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ABSTRACT
THE PENETRANCE OF PANCREAS AGENESIS CASUED BY GATA6 MUTATIONS IS
MODIFIED BY A NON-CODING SNP
Siddharth Kishore
Paul Gadue

GATA6 is a critical regulator of pancreas development, with heterozygous mutations in
this transcription factor being the most common cause of pancreas agenesis. However,
patients harboring GATA6 mutations exhibit variability in disease phenotypes. We have
used a pancreatic agenesis patient-induced pluripotent stem cell model to study this
disorder. We found that after correcting the coding mutation in a pancreas agenesis
patient’s iPS cell line, GATA6 protein expression was comparable to other wild type
stem cell lines at the definitive endoderm stage of development but still depressed in
pancreatic progenitors. To investigate this finding, we screened the regulatory regions
of the GATA6 gene and identified a SNP in a 3’ regulatory region of GATA6, with the
patient carrying the minor allele variant. We tested the SNP in 32 further patients with
pancreatic agenesis caused by GATA6 mutations and found that the frequency of the
minor allele was enriched in the pancreatic agenesis cohort. The minor allele variant
disrupted binding of the orphan nuclear receptor RORα and reduced GATA6 expression
and efficiency of pancreas differentiation. Our work highlights a possible genetic modifier
contributing to the pancreatic agenesis phenotype in patients with GATA6 mutations and
shows the benefits of using pluripotent stem cells to study the effects of non-coding
genetic variants in modifying disease penetrance.
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CHAPTER 1: INTRODUCTION AND OVERVIEW

1.1 The pancreas
The human pancreas is an organ that develops in the foregut endoderm and originates
from two separate primordia, the dorsal and ventral buds that arise from either side of
the distal foregut endoderm. The pancreas is made up of a variety of distinct cell types
such as exocrine, ductal and endocrine cells (Figure 1.1). The exocrine cells, which
constitute a majority of the pancreatic tissue, secrete digestive enzymes such as
amylase, proteases, lipases and nucleases to the duodenum via the pancreatic duct that
runs through the middle of the pancreas. These enzymes catalyze the breakdown of
lipids, proteins and carbohydrates and play an important role in nutrient digestion (Shih,
Wang and Sander, 2013). The endocrine cells are scattered throughout the pancreas
and located in small tight clusters in structures known as the Islets of Langerhans. Within
the islets, vasculature, neurons and mesodermal derived stromal cells ensure the proper
functioning of the endocrine cells (Pan and Wright, 2011). The functioning of endocrine
cells are mostly independent of the exocrine pancreas. Each type of endocrine cell
within the islet produces a specific type of hormone. α-cells secrete glucagon, β-cells
secrete insulin, δ-cells secrete somatostatin, ε-cells secrete ghrelin and γ-cells secrete
pancreatic polypeptide (PP) (Da Silva Xavier, 2018). Glucose homeostasis is maintained
in the body by the α-cells, β-cells and δ-cells. α-cells secrete glucagon when blood
glucose is low and β-cells secrete insulin when blood glucose is high. δ-cells act as
negative regulators of α-cells and β-cells. δ-cells, ε-cells and γ-cells function to regulate
nutrient metabolism. Human islets are composed of 55% β-cells, 35% α-cells and 10%
δ-cells with all cell types intermixed within the islet architecture. The total number of
1

islets in an adult human pancreas can vary between 300,000 and 1,500,000 (Brissova,
Fowler, et al., 2005).

Figure
1.1: Anatomy of the human pancreas
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Figure 1.1: Anatomy of the human pancreas
The human pancreas is about 6 inches long and sits across the back of the abdomen, behind the
stomach. The head of the pancreas is on the right side of the abdomen and is connected to the
duodenum through a small tube called the pancreatic duct. The pancreas is comprised of exocrine
and endocrine cells. The exocrine pancreas makes and secretes digestive enzymes into the
duodenum. This includes acinar and duct cells with associated connective tissue, vessels, and
nerves. The exocrine components comprise more than 95% of the pancreatic mass. The endocrine
cells in the pancreas are the islets that make and secrete insulin, glucagon, somatostatin and
pancreatic polypeptide into the blood. The islets comprise 1-2% of pancreatic mass. Adapted from
Blausen.com staﬀ (2014).

1.1.1 Endocrine pancreas

Given the key role of pancreatic endocrine cells in maintaining glucose homeostasis and
in diseases such as diabetes, understanding how these cells develop and function is
very important. The endocrine population of the pancreas is organized into small
2

structures or mini-organs called islets of Langerhans. There are five types of endocrine
cells within the islet that produce specific type of hormones. α-cells secrete glucagon, βcells secrete insulin, δ-cells secrete somatostatin, ε-cells secrete ghrelin and γ-cells
secrete pancreatic polypeptide (PP) (Da Silva Xavier, 2018). The average size of an islet
is 108µM and the total islet mass represents 1 to 2% of the pancreas (Ionescu-Tirgoviste
et al., 2015; Da Silva Xavier, 2018). The islets are highly vascularized structures that
have five times more capillaries than exocrine pancreatic tissue and receive 5-15% of
the entire pancreatic blood flow even though they consist of only 1-2% of the pancreatic
mass (Ballian and Brunicardi, 2007). Islet architecture varies between species with
striking differences seen when comparing human and mouse islets. In the mouse, the
inner core of the islet is mainly β-cells and is surrounded by α-cells and δ- cells, while in
humans the cells are scattered throughout the islet. Another key difference is in the
proportion of α-cells to β-cells between mouse and human. The average cell
composition of mouse islets is 77% β-cells and 18% α-cells whereas in humans it is 55%
β-cells and 38% α-cells (Cabrera et al., 2006; Dolensek, Rupnik and Stozer, 2015).
These differences in islet structure between species have an impact on islet physiology
and function, specifically related to calcium flux, metabolism and mitochondrial function
(MacDonald et al., 2011; Gregg et al., 2016).

The transcription factor Neurogenin3 (NGN3) plays an essential role in endocrine
development since it influences the expression of a diverse number of well-known
transcription factors involved in pancreas development and β-cell function (PDX1,
NKX6.1, SOX9, NKX2.2, NEUROD1, PAX4, RFX6, PAX6, GLIS3 and others) (Gasa et
al., 2004). NGN3 is a master regulator that specifies all 5 cell types of the endocrine
3

pancreas (Habener, Kemp and Thomas, 2005; Murtaugh, 2007; Sheets et al., 2018).
While the development of individual endocrine cell populations from Ngn3+ cells is still a
matter of active research, it is known that counteracting transcriptional networks induce
α-cells and β-cells. ARX and PAX4 are two transcription factors that repress each other
and help define the α- versus β-cell populations. ARX drives the α-cell formation, and
PAX4 is critical for β- and δ-cell formation (Collombat et al., 2005; Kordowich et al.,
2012). Increasing our understanding of the extrinsic as well as intrinsic mechanisms that
control these processes should facilitate the efforts to generate surrogate β-cells from
human pluripotent stem cells (hPSCs), or to reactivate the function of important cell
types within pancreatic islets that are lost in diabetes.

1.1.2 Exocrine pancreas

The exocrine pancreas is responsible for secretion of digestive enzymes, ions and water
into the duodenum of the gastrointestinal tract. The digestive enzymes are essential for
processing foodstuffs in meals to molecular constituents that can be absorbed across
the gastrointestinal surface epithelium. Although enzymes from salivary glands, the
stomach and the surface epithelium of the gastrointestinal tract also participate in the
digestion of a meal, the exocrine pancreas plays a central and essential role in the
digestive process. With loss of exocrine pancreatic function, absorption of nutrients in
markedly compromised and malnutrition ensues (Pandol, 2010).

4

The secretion of ions and water is also an essential function for the exocrine pancreas.
The flow of ions and water is necessary to transport the digestive enzymes from their
origin in the pancreatic acinar cells to the intestine. In addition, the pH of the pancreatic
secretions is alkaline due to a very high concentration of NaHCO3 (up to 140 mM). At
least one major function of the NaHCO3 is to neutralize the acidic pH of the gastric
chyme delivered to the intestine from the stomach. A neutral pH in the intestinal lumen is
necessary for optimal function of digestive enzymes as well as gastrointestinal surface
epithelial function (Pandol, 2010).

Anatomic studies demonstrate that the blood flow from the endocrine pancreas enters
the capillaries of the exocrine tissue surrounding each of the islets before entering the
general circulation (Ballian and Brunicardi, 2007). This “portal” system provides for the
delivery of very high concentrations of hormones from the islets to the exocrine tissue
surrounding the islets. The hormones from the islets include insulin, amylin, glucagon,
somatostatin and PP. Although the full significance of the effects of these hormones on
the exocrine pancreas is not known, the acinar cells that are involved in the regulation of
digestive enzyme synthesis of the exocrine pancreas have insulin receptors
(Pierzynowski et al., 2018).

The signaling pathways underlying the development process include the Hedgehog
system, the homeobox gene PDX1 and Notch signaling (Kim and MacDonald, 2002;
Habener, Kemp and Thomas, 2005). Inhibition of Hedgehog signaling leads to ectopic
budding of pancreatic structures in the stomach and duodenum (Parkin and Ingham,
2008). PDX1 expression in the gut tube during development marks the location of
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pancreatic bud development. Notch signaling inhibits endocrine cell differentiation and
promotes exocrine cell differentiation (Kim et al., 2010).

1.2 Development of the human pancreas
Embryogenesis in humans lasts ~ 8 weeks post conception, after which the embryo is
referred to as a fetus. Embryogenesis is marked by the specification of the 3 germ
layers: ectoderm, mesoderm and endoderm. All adult tissues originate from these 3
germ layers. Based on a morphological scheme and staged by extension of time i.e.
days post-coitum (dpc), human embryonic development is divided into 23 different
Carnegie Stages (CS) (O’Rahilly and Muller, 2010). Using this classification, human
pancreas development can be segmented into different Carnegie Stages, highlighted by
the morphology of the pancreas as well as expression of key transcription factors
(Jennings et al., 2015a). Figure 1.2 highlights the signaling events and transcriptional
networks that orchestrate the highly complex step-wise process of human pancreas
development.

During early development, the region of the foregut endoderm from which the pancreas
will arise is pre-patterned. Pancreas induction begins with the ventral and dorsal
thickenings of the epithelial cells in the distal foregut, which occurs at CS9 (Piper et al.,
2004). During this stage, the definitive endoderm (DE) maintains communication with the
visceral endoderm of the yolk sac (Jennings et al., 2013). Following this, at CS10,
endodermal folding specifies the foregut and hindgut. This folding restricts the opening
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of the yolk sac to the midgut (Jennings et al., 2013). The site of pancreas specification
lies at the foregut-midgut boundary, which is known as the anterior intestinal portal (AIP).
Figure
Stagesofofthe
human
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Figure 1.2:
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humanpancreas
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Figure 1.2: Stages of the human pancreas development
An illustration showing the timeline of human pancreas development from pluripotent stem cells in
the inner cell mass of the blastocyst to fate committed islet, ductal and acinar cells. Key
transcription factors that govern developmental stages and cell identity are highlighted. CS,
Carnegie Stage; dpc, days post coitum; wpc, weeks post coitum.
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The AIP has a lack of expression of sonic hedgehog and requires the expression of
retinoic acid (Apelqvist, Ahlgren and Edlund, 1997; Kim and Melton, 1998; Hebrok, Kim
and Jacques, 2000). The presumptive pancreatic endoderm is characterized by the
expression of PDX1, PTF1A and SOX9. At this stage the pancreatic epithelium is tightly
surrounded by mesenchyme, which expresses FGF10 at high levels. FGF10 regulates
expression of PTF1A and SOX9 and is important for cell proliferation and expansion of
the early pancreatic buds once they form (Pan and Wright, 2011; Shih, Wang and
Sander, 2013). In humans, PDX1 is first detected at CS12, even though SHH could still
be detected at CS10, which suggests a slightly later timing for the exclusion of SHH in
humans (Jennings et al., 2013).

The pancreas begins to develop by forming as two epithelial buds, a ventral and a dorsal
pancreatic bud at opposite sides of the foregut endoderm by evagination into the
surrounding mesenchyme. In both mouse and human, the dorsal bud forms first from the
dorsal foregut endoderm. By CS13, the dorsal and ventral pancreatic buds are clearly
defined and are marked by the transcription factors SOX9, PDX1, GATA4 and GATA6
(Piper et al., 2004; Jennings et al., 2013), all of which play a pivotal role in promoting
human pancreatic growth (Stoffers et al., 1997; Lango Allen et al., 2012; Shaw-smith et
al., 2014). The emergence of the dorsal bud appears to be regulated by extrinsic cues
from the surrounding vascular endothelial cells. This is followed by the evagination of the
ventral pancreatic bud along with the liver from the ventral foregut endoderm. The
ventral pancreatic bud receives cues form the cardiac mesoderm and the vitelline veins
(Gittes, 2009; Pan and Wright, 2011). The human pancreas continues its expansion of
proliferative progenitor cells for the remainder of the embryonic period. A unique aspect
8

of human pancreas development is the lack of early pancreatic endocrine differentiation
as compared to mouse and chick embryos, which display significant early pro-endocrine
patterning (Lammert, Cleaver and Melton, 2001; Bonal and Herrera, 2008; Villasenor et
al., 2010; Jennings et al., 2013; Otter and Lammert, 2016). Another notable difference
between the human and mouse pancreatic development is that transcription factor
NKX2.2 is detected in these progenitor cells of the mouse but not human (Jennings et
al., 2013).

As the multipotent pancreatic progenitor cells continue to proliferate there is a
segregation and change in morphogenesis of the pancreatic buds (Shih, Wang and
Sander, 2013). The buds elongate and as the gut tube rotates, the ventral and dorsal
buds come into contact and fuse together. At CS19, multiple small protrusions then
begin to form from the edge of the of the pancreatic bud (Gittes, 2009). The divergence
into “tip” or “trunk” progenitor cells is marked by the expression levels of GATA4
(Jennings et al., 2013). Tip cells that are located toward the edge of these protrusions
are in the tip domain and express PTF1A, C-MYC and CPA (Shih, Wang and Sander,
2013). Tip domain cells are fated to become acinar cells. As development progresses
acinar cells will continue to proliferate and increase in number by duplication (Pan and
Wright, 2011). Trunk cells, which commit to central duct-like structures, express lower
levels of GATA4 as compared to the more peripheral clustered pro-acinar tip cells, even
though both progenitor cell types express several common pancreatic markers such as
PDX1, SOX9 and NKX6.1 (Figure 1.2). Cells that are located toward the inside of the
buds in the trunk domain are also characterized by the expression of NKX6.2, TCF2,
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HNF6, PROX1 and HES1. Trunk domain cells are bipotential and give rise to endocrine
and ductal cells (Shih, Wang and Sander, 2013).
The trunk domain consists of ductal and endocrine progenitor cells. The ductal
progenitors form the primitive duct (or also known as the epithelial cord), which is
characterized by tubules lined by a single layer of polarized epithelial cells. The
commencement of endocrine specification is marked by the transient expression of
transcription factor NGN3 (Figure 1.2). Cells that lack the expression of NGN3 will
become the ductal cells. NGN3 positive endocrine precursors delaminate from the
primitive ducts, converting to non-epithelial cells through a process thought to involve an
epithelial-to-mesenchymal transition (Pan and Wright, 2011; Shih, Wang and Sander,
2013). In humans, NGN3 expression is detected at CS21 (8 wpc) around the end of the
first trimester of human pregnancy upon the formation of fetal β-cells (Piper et al., 2004;
Lyttle et al., 2008). These cells migrate into the surrounding area and coalesce into
aggregates that become the islets of Langerhans (Gittes, 2009). At 10 to 14 wpc, NGN3
expression is at its peak level. This expression declines around 18wpc and is detected at
extremely low levels after 35wpc (Salisbury et al., 2014). SOX9 is absent in cells
robustly expressing NGN3 and continues to be absent in subsequent endocrine cells,
but is present in pancreatic duct cells (Jennings et al., 2013). Each endocrine precursor
cell will further differentiate into one of the five types of hormone expressing cells. At 1213 wpc, islets containing α-cells, β-cells, δ-cells and γ-cells are apparent. α-cell fate is
determined by the expression of ARX while β-cell identity is determined by PAX4, PDX1
and NKX6.1 (Shih, Wang and Sander, 2013).

10

1.3 Key transcription factors of human pancreas development
Transcription factors are gene regulatory proteins that play an integral role in governing
gene regulatory networks and determining cell fate. During human pancreas
development certain transcription factors play a key role in directing cell fates by
regulating the transcription of genes involved in specification and ultimately mature
function. Much of what is known of transcription factors in pancreas development has
been revealed in rodent model systems such as genetically manipulated mouse models
and cell lines (Conrad, Stein and Hunter, 2014). Although these models are great tools,
there are notable distinctions between mouse and human pancreas, with implications in
development and function. Some of the transcription factors that play a vital role in
promoting human pancreatic development, function and identity are described below.

1.3.1 FOXA2

FOXA2 is a member of the winged helix/forkhead transcription factors and has been
reported to be necessary for DE formation (Dufort et al., 1998). FOXA2 transcription
factor is consistently expressed from week 4 forward during development (Jennings et
al., 2013). FOXA2 acts as a pioneer factor to regulate PDX1 expression in mice.
Recently this has been demonstrated in hPSC models of pancreas development as well
(Lee et al., 2002, 2019). FoxA2-/- mice have been demonstrated to be unable to develop
the foregut and midgut tissues (Dufort et al., 1998). FOXA2 persists in all mature
pancreatic cell types of both mice and humans.
11

1.3.2 SOX17

SOX17 is a member of the HMG (high mobility group) box group of transcription factors.
In humans, SOX17 is observed immediately before 4 weeks and is then excluded from
pancreatic cells about 1 week later. This pattern of expression is similar to the downregulation of sox17 during mouse pancreatic development (Piper et al., 2004). Mice
models have indicated that early sox17 expression is necessary for endoderm formation
and it represses pancreatic fate at later stages (Spence et al., 2009). During early
development, SOX17 is regulated by the Wnt/ β-catenin signaling pathway, which
promotes transcriptional activation of its target genes. SOX17 has also been shown to
be a direct regulator of FOXA1 and FOXA2 (Sinner et al., 2004). Sox17-/- mice and
hPSCs do not form DE. Additionally, SOX17 is required for the induction of PDX1
expression during pancreas specification (Kanai-Azuma et al., 2002).

1.3.3 HNF1B

HNF1B is a protein of the homeobox-containing basic helix-turn-helix family. HNF1B
expression can be detected at 7 weeks in humans, and persists throughout pancreatic
development (Jeon et al., 2009). Heterozygous loss-of-function HNF1B mutations result
in diabetes, termed MODY5, in humans. In mice only homozygous mutations show the
same phenotype suggesting a higher sensitivity to HNF1B dosage levels in humans
(Horikawa et al., 1997). This could also be due to a potentiated single wave of human
endocrine differentiation versus the two phases observed in mice. Hnf1b null mice die
before gastrulation due to defective visceral endoderm formation. Using tetraploid

12

complementation, it has been shown that Hnf1b null mice displayed pancreas agenesis
by e13.5 characterized by absence of the ventral pancreatic bud and an extremely
reduced and transient dorsal bud (Haumaitre et al., 2005).

1.3.4 PDX1

PDX1, also known as insulin promoter factor 1 (IPF1), has been studied for its role
throughout all phases of pancreatic development. PDX1 is known to be critical during
early pancreatic development and is expressed in all pancreatic precursor cells
(Bernardo et al., 2009). PDX1 is broadly expressed at around 4 weeks with a high level
of expression being restricted later to adult human β cells (Lyttle et al., 2008; Jennings et
al., 2013). In mice, pdx1 is expressed at e8.5 in the primitive gut tube and it marks the
pre-pancreatic endoderm as well as parts of the stomach and duodenum. Pdx1 high
expression then becomes restricted mostly to rodent β cells by e15.5, where it regulates
the expression of Ins1, MafA, and Pdx1 (Guz et al., 1995; Offield et al., 1996; Stoffers et
al., 1997).Low PDX1 expression is observed in the exocrine pancreas (Pan and Wright,
2011). In humans, PDX1 appears slightly later than in mice. Expression is only evident
after the notochord and aorta are separate from the dorsal foregut in humans (Jennings
et al., 2013). Homozygous loss-of-function mutations in PDX1 result in pancreatic
agenesis. Autosomal recessive mutations in the PDX1 locus have also been reported to
cause permanent neonatal diabetes (Brissova, Blaha, et al., 2005). PDX1 is commonly
used as a marker for early pancreatic progenitors during the differentiation of hPSCs.
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1.3.5 NKX6.1

NKX6.1, a member of the homeobox family of transcription factors, is a key regulator of
pancreas development. The absence of nkx6.1 expression in deficient mice leads to
impaired β-cell differentiation (Sander et al., 2000). Expression of NKX6.1 is detected in
the human pancreas from week 7 of development, gradually increasing from week 7 to
week 21 (Jeon et al., 2009). During human development, NKX6.1 is first detected, most
readily in the dorsal pancreatic bud, at CS13 (30–33 dpc). By CS15 (35–37 dpc),
NKX6.1 is co-expressed with PDX1, FOXA2 and SOX9 in pancreatic epithelial cells.
This profile of NKX6.1, PDX1, SOX9, and FOXA2 distinguishes multipotent pancreatic
progenitors in hPSC differentiation protocols (without NKX6.1, a combination of FOXA2,
SOX9, and weak PDX1 detection could indicate extrahepatic biliary duct cells) (Jennings
et al., 2013). Additionally, in the adult human pancreas, the maintenance of β-cell
identity is associated with the presence of PDX1 and NKX6.1 and changes in their
expression and/or localization have been described in the islets of type 2 diabetic
individuals. One theory suggests that the loss of β-cell identity possibly contributes to βcell dedifferentiation (i.e. the regression to a progenitor-like state) in this disease
(Marchetti et al., 2017).

1.3.6 PTF1A

PTF1A is a basic helix-loop-helix (bHLH) transcription factor that forms part of the PTF
complex. PTF1A plays a critical role in early pancreas specification from foregut
endoderm (Kawaguchi et al., 2002). In humans, PTF1A is detected at as early as 9 dpc
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in the pancreas buds. From 14 dpc and on, it PTF1A is expressed only in the exocrine
part of the pancreas. PTF1A was shown to play a key role in acinar development in
mice, as homozygous ptf1a null mutant mice fail to develop acinar cells (Krapp et al.,
1998). Evidence from these early studies suggested that Ptf1a is a specific determinant
for exocrine pancreatic cells only. However, lineage tracing studies in mice revealed that
most pancreatic multipotent progenitor cells (MPCs) express Ptf1a, and are capable of
differentiating into acinar, ductal or endocrine cells (Kawaguchi et al., 2002; Pan et al.,
2013). When Ptf1a activity is totally inactivated, most of the MPCs are converted into
non-pancreatic cell fates, such as gut and gallbladder. Haploinsufficiency or low levels of
Ptf1a promote endocrine cell fates while repressing exocrine cell fates, and vice versa
(Dong et al., 2008). These findings underscore the distinct roles of Ptf1a in the
specification and expansion of pancreatic progenitor cells. In later development and
adulthood, Ptf1a promotes acinar differentiation and regulates acinar cell-specific gene
expression, which is dependent on the PTF complex (Jin and Xiang, 2019). In humans,
heterozygous mutations in PTF1A or a downstream enhancer of PTF1A cause pancreas
agenesis (Sellick, Barker, Stolte-dijkstra, et al., 2004; Weedon, Inês Cebola, et al.,
2014).

1.3.7 SOX9

SOX9 is a member of the SRY/HMG box family. In mice, Sox9 is highly expressed in
both emerging pancreatic buds at e9.5 when they comprise almost exclusively of
multipotent progenitors (Seymour, 2014). Sox9 also colocalizes with Pdx1 in early (by
e9.0) dorsal and ventral pancreatic endoderm. By e12.5, Sox9 expression is barely
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evident at the periphery, denoting Sox9 withdrawal from the distal tips. Concordantly,
Sox9 becomes confined to trunk epithelium. In line with this proximal expression pattern,
the distribution of Sox9 signal at birth is interpreted as marking a subset of ductal cells,
islets, and a few acinar cells. The pattern of expression has led to Sox9 being
considered a pancreatic progenitor marker (Seymour, 2014). In humans, it has been
shown that SOX9 is weakly coexpressed with PDX1 in prospective duodenal-pancreatic
endoderm by CS12 (29-31 dpc), equivalent to ~e9-9.5 in mouse embryogenesis
(Jennings et al., 2013). By CS13 (30-33 dpc ≈e9.5-10 in mouse), SOX9 is strongly
expressed in the dorsal and ventral pancreatic buds and is maintained through CS16
(37-40 dpc ≈e12.25-12.75) in the branched pancreatic epithelium. The process of
segregating SOX9 to the proximal trunk appears to occur relatively late during the
human pancreatic program, between 10-14 wpc (weeks post-coitum). SOX9 rarely
colocalizes with late endocrine progenitor markers and is excluded from all differentiated
endocrine and acinar cells. This is consistent with SOX9 being enriched in pancreatic
progenitors while being largely excluded from endocrine progenitors and differentiated
endocrine and acinar cells (Seymour, 2014).

1.3.8 RORα

RORα is part of a family of nuclear receptors, also consisting of RORβ and RORγ, that
can function as transcription factors to regulate gene expression (Chai et al., 2013).
They bind as monomers to the consensus DNA motif RGGTCA and can act as an
“orphan” nuclear receptor to activate transcription even in the absence of bound ligands
(Chauvet et al., 2011). Ligand binding could lead to the recruitment of either co-activator
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or co-repressor complexes, which suggests that RORα could act as either a repressor or
activator of gene expression (Solt and Burris, 2012). A study of human embryos from
late CS12 to early CS14 using laser capture of the developing pancreas and liver have
suggested a specific role for RORα in regulating pancreas development (Jennings et al.,
2017). Of the 655 transcription factors identified as key pancreatic regulators in this
study, 44% were predicted to be regulated by RORα using motif discovery. These
studies highlight the potential role for RORα as a regulator of the pancreatic program in
humans. Phenotypes observed in RORα mutant mice revealed a role for RORα in
modulating diet-induced obesity, insulin sensitivity and glucose uptake (Lau et al., 2011;
Billon, Sitaula and Thomas P Burris, 2017). Studies have also shown the expression of
ROR receptors in pancreatic islet cells and RORα regulates the expression of Ins2 in rat
INS-1 cells (Mühlbauer et al., 2013; Kuang et al., 2014). Moreover, RORα was identified
as a diabetes susceptibility locus in Mexican Americans and Han Chinese (Hayes et al.,
2007; Zhang et al., 2016).

1.3.9 GATA6

GATA6 is a part of the GATA family of transcription factors that bind to the consensus
sequence A/T-GATA-A/G. GATA4, GATA5 and GATA6 are the GATA family members
found in endoderm derived tissues, the heart and gonads (Molkentin, 2000; Viger et al.,
2008). GATA6 consists of 7 exons with a total of 3770 base pairs; it contains two
transactivation domains followed by 2 zinc finger DNA binding domains and a nuclear
localization signal (Figure 1.3). GATA6 has two transcriptional start sites, both located in
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the second exon resulting in the production of two isoforms of GATA6, one which is 595
amino acids in length and the other 449 amino acids long (Brewer et al., 1999). The
human and mouse GATA6/Gata6 gene was first described in 1996 (Morrisey et al.,
1996; Suzuki et al., 1996). In humans, the GATA6 gene is located on human
chromosome 18 q11.1–q11.2 (Suzuki et al., 1996). During development, GATA6 is
expressed in the primitive streak, heart, lung and pancreatic tissues (Koutsourakis et al.,
1999; Liu et al., 2002; Sartori et al., 2014). In adult tissues, GATA6 transcripts were
expressed at high levels in the heart, ovary, lung, and pancreas, low levels in the liver
and spleen. GATA4 expression often overlaps with GATA6 expression in the adult
pancreas and heart (Suzuki et al., 1996).

Figure 1.3: Structure of the GATA6 gene and protein
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Figure 1.3: Structure of the GATA6 gene and protein
Representation of the gene structure of GATA6 (top) and protein (bottom). TAD, Transcriptional
activation domain; ZnF, Zinc finger DNA binding domain; NLS, Nuclear localization signal.

GATA6 plays a critical role in human pancreatic development. While investigation of
GATA6 in human development has been limited, it is expressed throughout the
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pancreatic progenitor cell population at CS16-CS18 (Cebola et al., 2015). During in-vitro
differentiation, GATA6 is expressed from the primitive streak throughout the
differentiation towards pancreas progenitors. During the later stages of development,
GATA6 becomes restricted to the endocrine pancreas and ductal cells (Decker et al.,
2006). Loss of GATA6 in mice does not affect glucose tolerance or insulin levels when
examined as adults (Carrasco et al., 2012; Xuan et al., 2012). Additionally, a conditional
loss of GATA6 in adult β-cells leads to increased endoplasmic reticulum stress and
minor β-cell death but does not have any effect on β-cell mass or glucose homeostasis
(Sartori et al., 2014). This suggests that GATA6 is not required in the endocrine
compartment in mice during the later stages of development and in the pancreas of adult
mice, GATA6 plays a non essential role in β-cell functionality. However, GATA6 is
required in the exocrine pancreas for the maintenance and functionality of acinar cells. In
mice with a lack of GATA6, the acinar cells are gradually lost resulting in the majority of
the pancreas being replaced by fat (Martinelli et al., 2013).

Recently, GATA6 has been revealed to be the most common cause of PA in a cohort of
27 neonatal diabetic patients with pancreatic agenesis or severe pancreas hypoplasia
(Lango Allen et al., 2012). Patients with a heterozygous mutation in GATA6 have been
found with a range of phenotypes from no pancreatic defects to adult onset diabetes and
pancreatic agenesis(De Franco, Shaw-Smith, Sarah E. Flanagan, et al., 2013). While, a
majority of GATA6 mutations in patients with pancreatic agenesis are de novo
mutations, in rare cases where the mutation is inherited. However not all patients with
the same mutation display the same phenotype suggesting incomplete penetrance.
There have been studies of pancreatic agenesis patients and family members with
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identical GATA6 mutations who have adult onset diabetes or even no abnormalities of
the pancreas (Bonnefond et al., 2012; De Franco, Shaw-Smith, Sarah E. Flanagan, et
al., 2013; Yu et al., 2014).

Mice models have proven to be useful in understanding the role of GATA6 in
development. However, mice with heterozygous loss of GATA6 are fertile and
phenotypically normal (Morrisey et al., 1998; Carrasco et al., 2012; Xuan et al., 2012).
Mice with homozygous GATA6 null alleles have shown that GATA6 is essential for extra
embryonic endoderm formation and leads to embryonic lethality (Morrisey et al., 1998).
However, it has also been shown that GATA6 null ES cells can form definitive endoderm
and contribute to the primitive gut tube (Koutsourakis et al., 1999; Zhao et al., 2005). In
mice, pancreas specific deletion of both GATA6 and GATA4 leads to pancreatic
agenesis, suggesting a species-specific dosage requirement of these GATA factors
(Carrasco et al., 2012; Xuan et al., 2012). In humans a heterozygous loss of GATA6
results in more severe phenotypes in comparison to murine models. Haploinsufficiency
of GATA6 may be occurring in human patients while this may not be the case in murine
models. Additionally, GATA4 and GATA6 may have greater functional redundancy in the
mouse as compared to humans and thus in mouse models, a heterozygous loss of
GATA6 can be compensated for with GATA4. To study a loss of GATA6 in a human
based system we chose to use the differentiation of hPSCs.
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1.4 Diseases of the human pancreas
There are various pancreatic diseases that affect humans. As our understanding of the
human pancreas has increased, these diseases have been studied extensively and
many therapies and potential cures have been developed. The major disease related to
the endocrine pancreas is diabetes, where patients lose their sensitivity to glucose
leading to higher blood glucose levels. There are many different forms of diabetes that
will be discussed below. Additionally, some forms of pancreatic disorders are caused by
developmental defects leading to neonatal diabetes mellitus (NMD). In some cases
these developmental defects lead to patients being born with minimal to no pancreatic
tissue. This is termed as pancreatic hypoplasia or pancreas agenesis (PA). The advent
of hPSCs to model human pancreas development has vastly expanded our knowledge
of developmental disorders associated with the pancreas.

1.4.1 Diabetes Mellitus

Diabetes is one of the oldest known diseases in human history. Indian texts dated from
the 5th century BC describe people with symptoms of polyuria and increased thirst. In
the past, diagnosis of diabetes was based on tasting the urine, as patients with this
disorder would excrete glucose in the urine. In 1674, Thomas Willis coined the name
diabetes mellitus, when he tasted dried urine from diabetic patients and described it as
sticky and similar taste to honey (quasi melle) (Eknoyan and Nagy, 2005). Diabetes
mellitus is rapidly becoming one of the largest and most expensive risks to global public
health (Whiting et al., 2011; Chan and Luk, 2016). Currently, approximately 8.5% of the
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world population has some form of diabetes, and this prevalence is projected to continue
to increase (Wareham and Herman, 2016). The global prevalence of diabetes has nearly
doubled since 1980, rising from 4.7% to 8.5% in the adult population and causing 1.5
million deaths in 2012 (World Health Organization, 2016). It is estimated that 366 million
people were diagnosed with diabetes in 2011; by 2030 this will have risen to 552 million
(International Diabetes Federation, 2011). In 2017 alone, treatment costs related to
diabetes in the United States rose to 327 billion dollars (Association, 2018).
Unfortunately, diabetes has significant associated mortality, ranking as the sixth leading
cause of death in the world and contributing to the mortality of other conditions such as
cardiovascular and renal disease (Ashcroft and Rorsman, 2012; Zheng, Ley and Hu,
2018).

Diabetes mellitus results from impaired insulin secretion or action, or both, resulting in
high serum glucose levels (Seino, Shibasaki and Minami, 2011). Despite decades of
research, our understanding of the underlying pathogenesis of diabetes, especially
pancreatic β-cell dysfunction, remains incomplete. In humans, physiological levels of
blood glucose prior to meals are typically 3.9 mmol/L to 7.2 mmol/L (or 70 to 130 mg/dL)
and two hours after a meal should not be higher than 10 mmol/L (or 180 mg/dL). Blood
glucose levels in the body are regulated by the release of the antagonistic hormones
from α-cells and β-cells. During regular homeostasis, when blood glucose is low, α-cells
secrete glucagon stimulating the hepatic conversion of glycogen to glucose, which is
then released into the bloodstream. When blood glucose levels are elevated, β-cells
respond by releasing insulin causing the uptake, utilization and storage of glucose.
Furthermore, insulin also subdues the hepatic production of glucose resulting in the
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lowering of blood glucose levels (Saltiel and Kahn, 2001; Rhodes, 2005). Diabetes
Mellitus can be categorized into four main categories, type I diabetes, type II diabetes,
gestational diabetes and diabetes as a result of other causes. Other causes of diabetes
include monogenic mutations, diseases of the exocrine pancreas and drug or chemical
induced diabetes (American Diabetes Association, 2016).

1.4.1.1 Type One Diabetes Mellitus (T1DM)
T1DM, or juvenile-onset diabetes, accounts for approximately 5-10% of diabetic patients
and is caused by the chronic autoimmune destruction of insulin-secreting β cells, usually
leading to complete insulin deficiency or hyperglycemia. Hyperglycemia occurs when
blood glucose levels are high, and this can lead to serious health conditions such as
ketoacidosis, kidney failure, heart disease, stroke, and blindness. T1DM cases account
for 10% of the diabetic population, and it is the most common form of diabetes in
children <15 years of age. 90000 children are diagnosed every year, and currently,
~600000 children suffer from T1DM (Diaz-Valencia, Bougneres and Valleron, 2015).

The pathogenesis of T1DM and its molecular mechanism underlying this disease is not
entirely clear. However, one of the characteristics of T1DM is the recognition of islet
autoantigens by autoreactive CD4 (+) and CD8 (+) T cells and autoantibodies.
Autoantibodies against islet autoantigens are involved in autoantigen processing and
presentation by human leukocyte antigen (HLA) molecules. T cells that are specific for
β-cell autoantigens are detectable in patients with advanced T1DM, and are able to
recognize post-translationally modified peptides specific to β-cells (Katsarou et al.,
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2017). The early phase of this disease is asymptomatic as the pancreas has an excess
of β-cells. Autoantibodies can be detected at this stage, with disruption of glucose
homeostasis being seen only with a significant loss of mass of β-cell mass (van Belle,
Coppieters and von Herrath, 2011).

It is uncertain how T1DM is triggered, but after more than four decades of research,
different aspects have been considered, from genetics to environmental. First, T1DM is
a polygenic disease where genetic factors are necessary but not sufficient to cause the
disease. There is a concordance rate of 30-50% in monozygotic twins and 6-10% in
zygotic twins. An individual with a first degree relative with T1DM has a risk of 1 in 20,
and in the general population that ratio is 1 in 300, indicating the influence that genetics
plays while also demonstrating that even in a permissive genetic background, the
disease is not 100% penetrant (Atkinson, 2012). There are around 50 loci associated
with a susceptibility to develop the disease, with the HLA genes providing the most
substantial contribution of approximately 60%. HLA genes encode for molecules that
participle in antigen presentation and it is thought that HLA predisposes disease by
presenting specific autoantigens. Many other loci are being investigated to gain new
insights into genetic risk and autoimmunity (Concannon, Rich and Nepom, 2009).

Environmental factors are another component to may contribute to T1DM. One
hypothesis suggests that stressors in the environment cause the β-cells to over-work,
leading to exhaustion and β-cell damage, which trigger the immune response. Another
theory suggests that the prevalence of T1DM is higher in countries where continuous
improvement in sanitation and living standards lead to underused components of the
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immune system attacking itself (Kondrashova et al., 2013). Microbial infection with
antigens cross-reactive to autoantigens may also yield the autoreactive T cells
(Coppieters et al., 2012). Another hypothesis called North-South Gradient is based on
the observation that the highest incidence of T1DM is in Northern European countries,
suggesting that low serum vitamin D could be associated with the development of the
disease (Hypponen et al., 2001). While many environmental factors have been
proposed, the real cause of T1DM may be a combination of both genetic and one or
more environmental factors.

1.4.1.2 Type Two Diabetes Mellitus (T2DM)
T2DM also results in disrupted glucose homeostasis caused by impaired insulin
secretion, insulin resistance or both, as well as chronic inflammation (DeFronzo et al.,
2015). T2DM is characterized by insulin resistance, where insulin-sensitive target tissues
such as the pancreatic β-cells, liver, muscle or adipose cells do not respond adequately
to normal levels of insulin produced by intact β-cells. Consequently, this leads to
disruption of the pancreatic β-cell function and decreased β-cell mass. Although T2DM is
most prevalent in adults, there has been increasing evidence of this form of diabetes
affecting younger individuals (Fajans, Bell and Polonsky, 2001). T2DM accounts for 90%
of the reported diabetic cases, which are around 400 million adults that range from 20-70
years old (Zheng, Ley and Hu, 2018). Epidemiological studies show that development of
T2DM is associated with sedentary behavior, lack of sleep or oversleeping and smoking
cigarettes.
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Genetics may also play a role in causing T2DM (DeFronzo et al., 2015). Twin studies
have shown that the heritability of T2DM could be 20-80% depending on the population
examined. The risk of developing T2DM in a lifetime is 40% for individuals with one
affected parent and this increases to 70% when both parents have it (Ali, 2013).
Genome-wide association studies (GWAS) have also been used to identify risk genes
associated with T2DM. A number of common variants have been identified in
approximately 100 genes related with obesity (FTO, MC4R), cyclin-dependent kinase
(CDKAL1, CDKN2A, CDKN2B), transcription factors associated with β-cell function and
pancreas development (NEUROD1, HNF4A, HNF1A, TCF7L2, HHEX, PTF1A, PAX6,
PAX4), ion channels (SLC30A8, SLC16A1) and others (Ali, 2013; Fuchsberger et al.,
2016). It has not only been challenging to identify the underlying genetic causes, but
also to devise universal therapeutic strategies for T2DM. No cure has yet been found for
the disease. Several forms of treatment that currently exist, especially for obese
patients, include lifestyle modifications, treatment of obesity, oral hypoglycemic drugs,
and insulin sensitizers such as metformin that reduces insulin resistance.

1.4.1.3 Monogenic Diabetes
Patients with monogenic diabetes have a mutation in a single gene involved in β-cell
development or functionality. These mutations can be inherited as dominant or
recessive, or arise spontaneously. Monogenic diabetes occurs approximately in 1 to 2 in
100,000 live births (Greeley et al., 2010; Anik et al., 2015), which accounts for 1%-4% of
diabetes that are diagnosed in children (Rubio-Cabezas et al., 2014). Monogenic
diabetes can be subcategorized into neonatal diabetes and maturity onset diabetes of
the young (MODY).
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Neonatal diabetes mellitus (NDM) is a rare type of diabetes that occurs in the first six
months of life with an incidence of 1 in 160,000 live births. Usually, the mutation occurs
in genes related to pancreas development, insulin regulation or apoptosis. 8 different
genes have been implicated in NDM (IPF1, EIF2AK3, GCK, FOXP3, KCNJ11, ABCC8,
PTF1A and GLIS3) (Harries et al., 2006; Ashcroft and Rorsman, 2012; Hattersley and
Patel, 2017). The most common causes of NDM are activating heterozygous mutations
in ABCC8 and KCNJ11. These genes encode for the K-ATP channel in β-cells. The
unique sensitivity to ATP/ADP level changes induced by glycolysis makes this channel a
metabolic cell sensor regulating insulin secretion (Hattersley and Patel, 2017). The KATP channel promotes insulin secretion. When the channel is open, K+ ions efflux to
maintain the polarization of the cell membrane. When there is a change in ATP/ADP
ratio in the cell, the K-ATP channel closes and the cell membrane is depolarized which
triggers the influx of calcium and leads to a release of insulin granules. Activating
heterozygous mutations in ABCC8 or KCNJ11 reduces the ability of the K-ATP channel
to close and thus preventing glucose-induced electrical activity and insulin release which
results in NDM (Ashcroft and Rorsman, 2012). Patients with neonatal diabetes can be
divided into two subcategories: those that have transient neonatal diabetes mellitus
which resolves after a few weeks to months and those who have permanent neonatal
diabetes mellitus (Greeley et al., 2010).

Maturity onset diabetes of the young (MODY) is the most common form of monogenic
diabetes accounting for 1-2% of the total diabetes cases reported. MODY is
characterized by heterozygous mutations in a single gene involved in the fetal
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development of the pancreas or regulation of maturation and maintenance of beta cell
function. MODY was first characterized in the 1970’s and was described in patients with
mild or no disease progression (Tattersall, 1974). Patients did not require insulin for
treatment. In the 1990s the molecular characterization of different MODYs was revealed
and since then a total of 13 types of MODY have been described in the literature. The
four most common types of MODYs result from mutations in either HNF1α or MODY3
(30% to 50% of the cases), GCK or MODY2 (20% to 50% of the cases, HNF1β or
MODY5 (5% of the cases) or HNF4α or MODY1 (5% of the cases) (Steck and Winter,
2011). Patients with MODYs typically do not have the presence of pancreatic or islet
autoantibodies; have low insulin requirements and detectable c-peptide levels (RubioCabezas et al., 2014).

1.4.2 Pancreas Agenesis (PA)

Pancreatic agenesis (PA) is a rare disorder resulting from defective pancreatic
development. The prevalence of PA is less than 1 in 1,000,000 and around 50 cases
have been reported in the literature so far. Clinically, PA can be complete or partial, i.e.
the pancreas can either be totally absent or extremely reduced in size (pancreatic
hypoplasia). PA patients are diagnosed with NDM within the first 6 months of life and
have severe pancreatic exocrine insufficiency. Patients also suffer from intrauterine
growth retardation (IUGR) as a result of reduced insulin secretion in utero and are
diagnosed with hyperglycemia in the first days of life. These patients require insulin
treatment and exocrine enzyme replacement therapy. Diagnosis of pancreatic agenesis
can be made by imaging (MRI or ultrasound) showing reduction or absence of
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pancreatic tissue and measurement of fecal elastase that is often undetectable in
patients with pancreatic agenesis as a result of exocrine dysfunction.

Isolated incidences of PA have been described as early as 1969 (Dourov and BuylStrouvens, 1969). The first genetic cause for PA to be identified was an inactivating
mutation in PDX1 (Stoffers et al., 1997). The patient had a homozygous point mutation
that caused a frameshift and showed signs of exocrine pancreas deficiency as well as
hyperglycemia requiring insulin. Subsequently, other PDX1 mutations have also been
implicated in PA. The second gene noted to cause PA was pancreas specific
transcription factor 1a (PTF1A). PTF1A plays a fundamental role in early pancreas
specification from foregut endoderm (Kawaguchi et al., 2002).

In humans, a mutation in PTF1A resulting in truncation of the C-terminal region was
identified in a case of pancreatic and cerebellar agenesis (Sellick, Barker, Stolte-Dijkstra,
et al., 2004). Interestingly, a few cases of PA have recently been attributed to alterations
in a region 25 kb downstream of PTF1A (Weedon, Ines Cebola, et al., 2014; Gabbay et
al., 2017). This enhancer regulates the expression of PTF1A in human embryonic
pancreatic progenitor cells, and mutations in the enhancer leads to its inactivation and
PTF1A deprivation in these cells. One rare case of neonatal diabetes mellitus and
pancreatic agenesis was also reported with compound heterozygous mutation of PTF1A
(Gabbay et al., 2017). The patient had a deletion and frameshift mutation in the PTF1A
coding region on one chromosome, and a point mutation in the 400-bp enhancer region
on another chromosome.
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Figure 1.4: Pancreas Agenesis
During human development, the pancreatic buds appear around 4-5 weeks post coitum (wpc) and
develop into the dorsal and ventral pancreas by 8-9 wpc. In patients suffering with PA, the dorsal
and ventral panreatic regions are absent and patients are born with minimal or no pancreatic tissue.
Adapted from Langman’s medical embryology, 12th ed.

More recently, haploinsufficiency of GATA6, caused by heterozygous mutations, was
shown to be the most common cause of PA (Lango Allen et al., 2012). In these patients,
pancreatic agenesis is commonly associated with other extrapancreatic malformations
such as cardiac malformation, neurocognitive defects, hypothyroidism, gut abnormalities
and gallbladder agenesis/biliary atresia (De Franco, Shaw-Smith, Sarah E Flanagan, et
al., 2013). Investigation of GATA6 in human development has been limited, with its
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expression throughout the pancreatic progenitor cell population having been described
at a single time period, CS16-CS18 (Cebola et al., 2015). However, not all patients with
GATA6-inactivating mutations causing congenital heart disease show PA and diabetes,
and not all mutations arise de novo in the affected individual, implying some variability in
the clinical phenotype (Bonnefond et al., 2012). Conditional inactivation of Gata6 and
Gata4 in mouse and the data imply a degree of redundancy between the two factors
(Carrasco et al., 2012; Xuan et al., 2012). This redundancy between the GATA factors
seems less apparent in humans. However, a few cases of GATA4 mutation resulting in
PNDM and at least some degree of exocrine insufficiency have also been described
(Shaw-Smith et al., 2014).

1.5 Pluripotent stem cells:

Pluripotent stem cells (PSC) are cells that have the ability to indefinitely self renew in an
undifferentiated state and have the potential to be differentiated into any cell type in the
body. Embryonic stem (ES) cells are cells that are derived from the inner cell mass of
the blastocyst while induced pluripotent stem (iPS) cells are generated by introduction of
pluripotency factors. PSCs have the potential to give rise to unlimited supplies of
functional human cells that can be used in the study of developmental biology, disease
mechanisms, drug discovery and therapeutics (Girlovanu et al., 2015). The first
described isolation of human ES cells from the blastocyst was in 1998. The human ES
cells were derived from the inner cell mass of the human blastocyst and could be
maintained as colonies on a feeder layer (Thomson et al., 1998). The long-term
maintenance of these cells has been studied for many years and the optimal culture
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conditions for the maintenance of pluripotency with basic fibroblast growth factor (bFGF)
are well established, allowing the growth and propagation of human ES cells in in vitro
cultures (Yamanaka, 2012). Human ES cell lines were shown to have high telomerase
activity, be karyotypically stable and displayed pluripotency as they are able to form all
three germ layers in a teratoma assay. Human ES cells express the transcription factors
NANOG, OCT4 and SOX2. They also express the extracellular markers SSEA-3,
SSEA4, TRA-1-60 and TRA-1-81 (Thomson et al., 1998).

Given the relative limited access to ES cells from human embryo blastocysts, a lot of
effort has been put into inducing pluripotency in somatic cells, which culminated in the
development of induced pluripotent stem (iPS) cell technology. In 1962, the first
reprogramming of cells by somatic cell nuclear transfer was demonstrated. A nucleus
from the intestinal epithelium cell of a swimming tadpole stage was transferred to an
unfertilized egg and shown that the egg could successfully develop into a tadpole
demonstrating that development could be reverted to an earlier stage (Gurdon, 1962).
Additionally, in 1989, the transcription factor myosin D was identified as a master regular
whose expression could convert the cell fate of multiple cell lines to muscle cells
(Weintraub et al., 1989). This was a very early demonstration that the introduction and
expression of a transcription factor could change cell fate. Based upon these ideas, in
2006, the generation of iPS cells from both embryonic and adult mouse fibroblast cells
was first described. 24 transcription factors that are known to play roles in maintaining
pluripotency we screened by retroviral expression and this list was narrowed down to 4
necessary factors; oct3/4, sox2, c-myc and klf4 (Takahashi and Yamanaka, 2006). Their
work demonstrated that adult differentiated cells could be reprogrammed back to an
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embryonic stem cell state. The following year, human iPS cells were derived from adult
human fibroblasts using the same four transcription factors that were used to generate
mouse iPS cells (Takahashi et al., 2007).

The discovery of iPS cells was a large advancement in the field, as it provides a
potential for studying pluripotency without the ethical complications that may be
associated with the derivation of human ES cells and also a method to generate patient
specific stem cells. hPSCs have the potential to be used in disease models for studying
the molecular basis of diseases, including genetically inherited human diseases
(Yamanaka, 2012). It brings tremendous potential not only in disease modeling, but also
in regenerative medicine, cell replacement therapy, drug testing and targeted generepair strategies, such as homologous recombination to repair genetic defects. Thus,
they serve as ideal model systems for human developmental scientific studies.

1.6 Modeling pancreas development using stem cells
Using the knowledge derived from studying the embryonic development of various
model organisms, detailed protocols have been established to derive pancreatic cells
from hPSCs. The in vitro differentiation of hPSCs is achieved by sequential exposure to
growth factors based on known signaling pathways and mechanisms of development
(Figure 1.5). During in vivo embryonic development the process of gastrulation leads to
the formation of the primary germ layers, ectoderm, mesoderm, and endoderm (Tam
and Behringer, 1997).

In the mouse embryo, the primitive streak forms during
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gastrulation in the posterior side of the embryo at the border between the epiblast and
extraembyronic tissue. Uncommitted epiblast cells that will eventually become the
mesoderm and definitive endoderm (DE) germ layer undergo an epithelial to
mesenchymal transition and migrate through this structure. Epiblast cells that migrate
through the more posterior region of the primitive streak will form the mesoderm while
cells that migrate through the more anterior region of the primitive streak will form DE. In
vitro primitive streak differentiation is first established by the addition of the canonical
Wnt ligand, Wnt3a, or small molecules that can mimic this signal. Cells are then
differentiated to DE by the activation of Nodal signaling, a ligand for transforming growth
factor-β (TGF-β) superfamily, through the addition of high concentrations of the Nodal
surrogate, Activin A (Kubo et al., 2004; Gadue et al., 2006). Activin A is another TGF-β
family member and induces a similar intracellular signal as Nodal. The first stages of the
pancreatic differentiation protocols involve the differentiation of primitive streak cells into
DE cells using elevated concentration of Activin A (D’Amour et al., 2005).

As development of the endodermal germ layer proceeds, the primitive gut tube forms
organs buds that will proliferate and eventually differentiate into the mature organs. In
2006, a comprehensive stepwise pancreatic specification protocol was introduced,
describing the differentiation of hESCs to endocrine cells with the use of specific growth
factors and chemical compounds (D’Amour et al., 2006). With this in vitro differentiation
protocol, the cells mimic in vivo pancreas organogenesis by being directed through
stages resembling DE, gut-tube endoderm, pancreatic endoderm and endocrine
precursor, thus recapitulating the major stages of normal pancreatic endocrine
development. Each stage is recognized by the expression of specific markers. Soon
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after, improved pancreas differentiation protocol using serum-free media, retinoic acid
(RA) and nicotinamide was published (Jiang et al., 2007). The protocol had 4 distinct
stages: DE formation, pancreatic endoderm formation, endocrine induction and islet-like
cluster formation. These cells were produced insulin but showed limited responsiveness
to glucose stimulation.

This study was followed by various modified variations of pancreatic differentiation
protocols (Kroon et al., 2008; Zhang et al., 2009; Loh et al., 2014; Pagliuca et al., 2014;
Rezania et al., 2014; M Cristina Nostro et al., 2015; Russ et al., 2015). The Melton group
described the generation of glucose-responsive cells from hPSCs following an approach
of coaxing cells through different stages mimicking pancreas development. Cells were
coaxed to NKX6–1+/PDX1+ cells by employing previously published protocols. From
NKX6–1+/PDX1+ cells, β-cell-like cells (termed SC-β cells, ~33% NKX6–1+/C-peptide+)
emerged in 2–3 weeks. Non-NKX6–1+/C-peptide+ cells in the final population were αcells, δ-cells and PDX1+ pancreatic progenitors that had not differentiated into endocrine
cells. SC-β cells responded to 2–3 successive glucose challenges in vitro by releasing
insulin with a comparable stimulation index (ratio of insulin secretion at 20 mM to 2 mM
glucose) to that of primary human adult islets. Similar to the aforementioned report,
Kieffer and colleagues devised a 7-stage protocol for driving the fate of hPSCs to
pancreatic endocrine cells. Cells differentiating to pancreatic endoderm progeny
expressing PDX1/NKX6–1 (stages 1–4) were grown in a planar culture and then they
were plated as clusters onto filter inserts (air-liquid interface (ALI) culture) for the
remaining stages. More recently, refinements of the protocol, most notably the omission
of TGFβ signaling inhibitors at the β-cell maturation stage, now permit the generation of
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glucose-responsive β-cells in vitro (Nair et al., 2019; Velazco-Cruz et al., 2019; Veres et
al., 2019). It is important to note that these refined protocols were optimized to
predominantly produce β-cells for use in cell therapy and that other pancreatic cell types
are not generated to the same extent as seen during embryonic development. This could
limit the utility of these protocols for studying developmental mechanisms.

Despite significant recent advances in the differentiation of hPSCs into pancreatic cells,
several challenges remain to obtain functional human pancreatic – particularly insulinproducing – cells performing on par with native cells. The variability noted in different
reports in the specification outcomes across various hPSC lines points to the need for
protocol adaptation and optimization, generally hindering direct translation to multiple
lines. In addition, glucose-stimulated insulin secretion (GSIS) of many stem cell-derived
pancreatic cells differs significantly from that of primary human islets. More importantly,
the underlying causes of these discrepancies between native islet cells and hPSCderived cells are unclear. The ability to differentiate hPSCs to functional β-cells in vitro is
important for the study of the mechanisms of β-cell failure. PSCs with specific mutations
can be obtained through genome editing of ES cells or from diabetic patient derived iPS
cells. In vitro derived β-cells can also be utilized to investigate β-cell proliferation,
maintenance, in drug testing and provide the potential for the generation of an unlimited
supply of β-cells if these cells are to be used in tissue replacement therapy.
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1.7 Genetic modifiers of disease penetrance

While many of the strongest associations between genotype and phenotype are coding
mutations or variants, in a significant number of diseases there exists inter-individual
differences, termed ‘variable penetrance’ (Castel et al., 2018). Variable penetrance and
variable expression of genes are common phenomena that often cause individuals
carrying the same variant to display highly variable symptoms. This is true even in the
case of Mendelian and other severe diseases driven by rare variants that have a strong
effect on phenotype. These phenomena are a key challenge for understanding how
genetic variants manifest in human traits and a major practical caveat for the prognosis
of an individual’s disease outcomes based on their genetic data. However, the causes
and mechanisms of variable penetrance are poorly understood. In addition to
environmental modifiers of genetic effects, a potential cause of variable penetrance
involves other genetic variants with additive or epistatic modifier effects (Cooper et al.,
2013). While some studies have successfully mapped genetic modifiers of, for example,
BRCA variants in breast cancer (Milne and Antoniou, 2011) and RET variants in
Hirschsprung’s disease (Emison et al., 2005), the cause of variable penetrance in a
large number of diseases are unknown. In part, this is because large-scale genome-wide
association studies (GWAS) typically lack power and are easily affected by confounders
(Wei, Hemani and Haley, 2014). A targeted analysis of a specific variant or gene that is
strongly implicated in a rare disease typically suffers from a low number of carriers and
lack of an ideal model system for testing these diseases modifiers. A large-scale study in
2018 showed that non-coding regulatory variants could affect the penetrance of
pathogenic coding variants. By using diverse data types from population and disease
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cohorts, the study provided strong evidence of modified penetrance due to joint
functional effects of regulatory and coding variants. Importantly, this suggested that the
combination of an individual’s regulatory and coding variant genotypes has an effect on
phenotype, since purifying selection acts only on traits that affect fitness (Castel et al.,
2018).

Figure 1.6: The effects of non-coding regulatory variants on disease penetrance
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Figure 1.6: The effects of non-coding regulatory variants on disease penetrance
In certain monogenic diseases that display a variability in penetrance, the presence of non-coding
regulatory variant could affect functional protein expression and manifestation of the disease. In
the above illustration, if the non-coding variant is present in cis with the non-functional coding
allele, the functional allele produces enough functional protein to prevent a severe disease
phenotype. However, if the non-coding variant is present in trans with the non-functional coding
allele, the amount of functional protein produced from both alleles is reduced, resulting in a severe
disease phenotype.
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Interestingly, most of the single-nucleotide variants/polymorphisms (SNVs/SNPs) that
provide statistical evidence for increased risk of complex diseases have been mapped to
non-coding regions (Zhang and Lupski, 2015). While the risk variants revealed by
GWAS may be linked with a neighboring causative coding variant, an alternative and
more likely explanation is that functionally relevant genetic variants reside in non-coding
regions with functional consequences on nearby genes. Accumulating evidence has
shown that the GWAS variants are significantly enriched in the functional non-coding
regions such as enhancer elements, DNase hypersensitivity regions and chromatin
marks (Ahonen et al., 2009; Degner et al., 2012; Trynka et al., 2013). Functional noncoding variants can affect cis- or trans-regulatory elements, suggesting potential
genome interaction that can be investigated by various genome technologies.
Chromosome Conformation Capture (3C) enables the study of chromatin looping and
genome architecture in three dimensions; 3C has been used for functional annotation of
the schizophrenia-associated loci suggested by a genome-wide association study (Ripke
et al., 2013; Roussos et al., 2014). The schizophrenia-associated SNPs identified by
GWAS are located in the predicted enhancers downstream of CACNA1C. They map to
where the 3C assay in human dorsolateral prefrontal cortex and iPSC-derived neurons
revealed promoter–enhancer interaction through chromosome loops.

While computational methods enhanced by the growth of GWAS have been an
invaluable tool, functional assays are important experimental steps to investigate the
molecular mechanism of non-coding variants in human disease. A classic approach to
study the functional consequences of human disease-associated SNPs has been to
engineer variation into mouse models.
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In the past few years, the renovation and development of the CRISPR/Cas technology
enables the quick and accurate genome editing in various model organisms for both
SNPs and small indels (Shalem, Sanjana and Zhang, 2015). While evolutionary
conservation is still the prerequisite for functional assays of non-coding variants in model
organisms, when the non-coding variants of interest are not conserved in mouse, it has
also been feasible to directly obtain the human genetic variant of interest using the stem
cell technologies, such as patient-derived iPSCs, for further in vitro functional assays
(Donnelly et al., 2013; Sareen et al., 2013).

1.8 Studying genetic modifiers of disease penetrance using stem cells
Since their discovery over 10 years ago, iPSCs have been used to model a multitude of
“diseases in a dish” by utilizing lines derived from a relatively small number of diseased
and healthy donors (Avior, Sagi and Benvenisty, 2016; Warren et al., 2017). iPSCs can
be directly derived from the somatic cells of any donor prospectively identified to carry a
genotype of interest (Park et al., 2008). This versatile feature makes iPSCs an ideal
platform for the study of Mendelian or monogenic diseases. The differentiation of human
iPSCs to cell types of relevance offers a powerful platform with enormous potential for
disease modeling, drug screening, and cell therapeutics. The combination of human
iPSC technology with genome editing technique allows the generation of isogenic cell
lines that differ in single genetic changes for causal modeling of candidate variants and
genes, offering a new tool linking genotypes to phenotypes in the study of human cell
biology and disease (Fang et al., 2019).
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A good example of using iPSCs to model disease modifying SNPs is from the study by
Soldner et al. that demonstrated functional connect of GWAS-identified risk variants of
Parkinson’s disease in neurons derived from human iPSCs (Soldner et al., 2016). They
focused on Parkinson’s disease associated risk SNPs, which were located in a αsynuclein (SNCA) regulatory region based on genome-wide epigenetic information. They
were able to identify subtle changes in allele-specific transcription of SNCA between two
SNPs located in the SCNA enhancer region. As a follow up approach, they used
CRISPS/Cas9 to knock-out a single allele of the SNP and determine how the SNP
affected SNCA expression. They found that allele-specific expression roughly translated
to an increase of total SNCA expression in neurons and in neural precursors.
Furthermore, sequence-dependent binding of the brain-specific transcription factors
EMX2 and NKX6-1 on this locus was revealed.

Another example of disease modeling using iPSCs is presented by Ebert et al. (Ebert et
al., 2014). They studied a SNP in the gene coding for aldehydronease 2 enzyme, which
confers a loss of cardioprotective effects and increases the risk for coronary artery and
ischemic heart disease. Cardiomyocytes (CM) differentiated from iPSCs derived from an
east-Asian population genotyped for a common ALDH2* SNP (MAF = 0.08),
demonstrated that CMs carrying the ALDH2* genotype had increased levels of oxidative
stress and aldehyde byproduct 4HNE buildup. Accumulation of these two byproducts
resulted in dysregulated cell cycle and apoptosis signaling, which exacerbated damage
and reduced cellular recovery to ischemic challenge in the CMs of ALDH2* carriers,
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thereby establishing the cellular mechanisms for increased disease susceptibility for a
single SNP.

Hypertension (HTN), a common, complex and polyfactorial disease, that can be affected
by genetic variants which regulate blood pressure was studied by Hamazaki et al.
(Hamazaki et al., 2017). Animal models have been used intensively for studying
systemic diseases like HTN, however they may not always be suitable for understanding
the biological impact of human genetic variants. It is also difficult to obtain a large
number of appropriate tissues of relevance for the phenotype of interest (e.g., vascular
smooth muscle or endothelium) from a person with a specific genotype to test the
biological or functional consequences of these genetic variations. To combat such
challenges, Biel et al. constructed an iPSC repository from 17 HTN patients, whose
genome-wide SNP variations as well as clinical responses to antihypertensive drugs
were available (Biel et al., 2015). They then differentiated these iPSCs into vascular
smooth muscle cells and quantified their contraction in response to various physiological
stimuli. Furthermore, the study also demonstrated the ability of iPSCs to recapitulate a
SNP-associated modification of PRKCA expression.

It is increasingly important to understand how specific risk variants functionally contribute
to underlying pathogenesis. Compared with single gene mutation found in monogenic
diseases, the effects of SNP variants can often be minor or subtle. It is important to
utilize isogenic cells to decode the significance of such gene variants.
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Recent advances in genome-editing technology (e.g., CRISPR/Cas9 systems) have
simplified the ability to target specific genetic loci for functional studies.

1.9 Overview of Research Goals
While recent studies have implicated GATA6 as the most common cause of pancreatic
agenesis, the molecular mechanisms that regulate the development of this disease are
still not entirely understood. Additionally, the variability in penetrance of GATA6
heterozygous mutations raises questions regarding other factors that may influence
GATA6 levels that could lead to variability in phenotypes. The goal of this project is to
answer these questions and develop a deeper understanding of pancreatic agenesis
caused by GATA6 haploinsufficiency. The finding that a patient derived iPS line had a
more severe developmental phenotype as compared to an ES cell line with the same
GATA6 mutation piqued our interest in this project. Given the majority of known GATA6
mutations have been identified by sequencing the coding region of the gene, we
hypothesized that this variable disease penetrance is caused by differences in the noncoding region of the GATA6 locus that regulate its expression during development
(Rodriguez-Segui, Akerman and Ferrer, 2012; Yorifuji et al., 2012; Catli et al., 2013;
Suzuki et al., 2014; Yu et al., 2014; Christina S Chao et al., 2015; Stanescu et al., 2015).
We identified a non-coding SNP rs12953985, which lies approximately 8kb downstream
of the GATA6 gene, with the patient line harboring the minor allele variant (A) of this
SNP. Interestingly, we also found that the minor allele variant of this SNP was enriched
in a cohort of 33 total patients with pancreatic agenesis caused by GATA6 mutations.
Using CRISPR-CAS9 genome editing, we analyzed the effect of this variant on GATA6
expression during in vitro pancreas differentiation from multiple genetically matched
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hPSC lines. We found that the minor allele variant of rs12953985, in conjunction with a
GATA6 heterozygous mutation, led to the largest reduction in GATA6 protein expression
specifically during pancreas specification and a more severe defect in generating
pancreatic progenitors. We also determined that the minor allele variant of this SNP
impaired RORα binding by chromatin immune-precipitation (ChIP) assay. Inhibiting the
function of RORα using an inverse agonist decreased GATA6 expression and inhibited
pancreas development. This effect was observed only in lines with an intact RORα
binding site supplied by the major allele variant of the SNP. Finally, we modified the
minor allele variant of the SNP to a consensus RORα binding site in the GATA6 PA
patient iPSC line. We found that the iPSC line where both the coding mutation was
corrected and the RORα binding site is introduced has the highest levels of GATA6
expression and most efficient pancreas differentiation capacity. This study identifies a
possible genetic modifier contributing to the pancreatic agenesis phenotype in patients
with GATA6 mutations.
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CHAPTER 2: MATERIALS AND METHODS
2.1 EXPERIMENTAL MODEL AND SUBJECT DETAILS

2.1.1 hPSC lines

The Mel1 ES cells were obtained from Ed Stanley and Andrew Elafanty at the Murdoch
Children's Research Institute(Micallef et al., 2012). The CHOP.Panagenesis1 (patient
IPS+/indel) IPSC cells were generated from a lymphoblastoid cell line by reprogramming
using episomal vectors by the Stem Cell core at the Children's Hospital of Philadelphia.
The CHOPWT6 iPSC line was also reprogrammed by the Stem cell core at the
Children’s Hospital of Philadelphia and was previously published as the WTBM1-8 iPSC
line (Sullivan et al., 2014).

2.1.2 Monogenic Diabetes Registry

Patients Chicago#1-5 and N6320 were consented for the Monogenic Diabetes Registry,
an IRB-approved longitudinal study of people with monogenic diabetes housed at the
University of Chicago. Over 3,000 participants are currently enrolled in the Registry and
other associated studies. Information about the Monogenic Diabetes Registry can be
found at www.monogenicdiabetes.org.
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2.1.3 GATA6 testing at the Exeter Molecular Genetics laboratory

The probands of Exeter families 1 to 31 had been referred to Exeter for genetic testing.
The GATA6 gene (NM_005257.4) was tested either by PCR followed by Sanger
sequencing as previously described (De Franco et al., 2013) or by targeted next
generation sequencing of all the known monogenic diabetes genes (Ellard et al., 2013).
Clinical information was provided by the referring clinicians via a neonatal diabetes
request form (available at www.diabetesgenes.org) or from clinical notes. The study was
conducted in accordance with the Declaration of Helsinki principles with informed
parental consent given on behalf of children.

2.2 METHOD DETAILS

2.2.1 hPSC culture

hPSC cell lines were cultured on 0.1% gelatin and irradiated mouse embryonic fibroblast
(MEF) feeder cells in DMEM/F12 supplemented with 2mM of glutamine, 15% Knockout
Serum

Replacement

(KSR),

1X

NEAA,

penicillin/streptomycin,

0.1mM

β-

mercaptoethanol and 10ng/ml of bFGF. The medium was changed every day. Cells
were passaged when they reach 80% confluence, approximately every 4 days, using
TrypLE at a 1:6 ratio. In all hPSC cultures, 5 µM Rho-associated protein kinase (ROCK)
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inhibitor Y-27632 (Selleck Chemicals, #S1049) was only added into the culture media for
~18 hours when passaging or thawing hPSCs.

2.2.2 Generation of genetically modified hPSCs mediated by CRISPR-CAS9

The 19bp gRNA’s of interest were cloned into the vector (Addgene, #41824) using InFusion HD (Clontech Cat No. 639647). PSCs were plated onto gelatin coated 6-well
plates with MEF’s 24 hours prior to transfection and were transfected at 40% to 60%
confluency. 0.5µg CAS9-GFP (Addgene, plasmid #44719), 0.5µg gRNA, 0.5 µg of
ssODN and 3µL Lipofectamine Stem reagent was diluted separately in 50µL DMEM-F12
and gently mixed together. The mixture was incubated at room temperature for 10
minutes and added dropwise into 1 well of cells. 18 to 24 hours post transfection, cells
were harvested with TrypLE and cell sorted for GFP positive cells. These cells were
plated at low density (~1000-2000 cells / 10cm dish) in human ES cell maintenance
media with 5 µM ROCK inhibitor (Cayman chemicals) onto a 1:3 matrigel coated 10cm
tissue culture dishes containing MEFs. Approximately 14 to 20 days later single colonies
were manually picked and screened. To screen for positive clones, genomic DNA was
extracted from the clones by resuspending the cells in 20 µL of Accutaq PCR buffer
(Sigma-Aldrich) with 0.1 µg/mL proteinase K (Qiagen) and incubated at 55°C for 60
minutes followed by 95°C for 10 minutes. Cell debris was spun down and 5 µL of
supernatant was used for PCR. The PCR products were analyzed by 3.5% agarose gel
electrophoresis and sequencing. Heterozygous mutants were confirmed by sub-cloning
PCR products using the TOPO TA cloning kit (Life Technologies) sub-cloning of cells to
exclude potential contamination of cells with different genotypes (e.g., mixing of
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homozygous mutant cells with WT cells). All primers, guide RNA’s and single stranded
DNA oligos used for genome editing are listed in Table 2-1.

Table 2-1. Guide RNA’s, ssODN’s and primers

Guide RNA’s

Sequence 5’ to 3’

gRNA for
introducing 4bp
duplication in exon
2

AGTGGGCCAGCCAACCACGCGGG

gRNA for
introducing minor
allele variant of
rs12953985

GATGGAAGAGACTTGACTGAGG

gRNA for
introducing RORα
consensus

CTTGACTGAGGTCCAGCTGAGG

ssODN’s

Sequence 5’ to 3’

ssODN for
introducing 4bp
duplication in exon
2

TCCCCGGTCTACGTGCCCACCACCCGCGTGGGTTCCA
TGCTGCCCGGCCTACCGTACCACCTGCAGGGGTCGGG
CAGTCAGTGGGCCCGCGAATCATGCAGGCGGCGCGG
GCGCGCACCCCGGCTGGCCTCAGGCCTCGGCCGACA
GCCCTCCATACGGCAGCGGAGGCGGCGCGGC

ssODN wild-type
exon 2

TCCCCGGTCTACGTGCCCACCACCCGCGTGGGTTCCA
TGCTGCCCGGCCTACCGTACCACCTGCAGGGGTCGGG
CAGTGGGCCCGCGAATCATGCAGGCGGCGCGGGCGC
GCACCCCGGCTGGCCTCAGGCCTCGGCCGACAGCCCT
CCATACGGCAGCGGAGGCGGCGCGGC

ssODN for
introducing minor
allele variant of
rs12953985

TACTGACGAACCACAACCCAACCTTTCTGAGACTCAGT
TTCCTCAGCT

ssODN for

TACTGACGAACCACAACCCAACCTTTCTGAGACTCAGT

GGACTTCAGTCAAGTCTCTTCCATCTCTAAAGTTATATG
AATTGATGA
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introducing RORα
consensus

TTCATCAGCTTGACCTCAGTCAAGTCTCTTCCATCTCTA
AAGTTATATGAATTGATGAGCTGGACCTCAGTCAA

Primers

Sequence 5’ to 3’

PCR primer’s for
4bp duplication in
exon 2

Forward- CGGAGGAGATGTACCAGACC

Sequencing
primer’s for 4bp
duplication in exon
2
PCR primer’s for
R5

Sequencing
primer’s for R5

Reverse- CTGGGAGAGTAGGGGAAGC
Forward- TTCGTGCACTCTGCG
Reverse- TGAGGCCAGCCGGGGTGC
Forward- GGTGTTGTCTGATTAAGGAAATCTAGGTACC
ReverseATAAATTATAAGTAACAAGCAACCGGTGTTCCC
Forward- GGAAATCTAGGTACCTCACACTGC
Reverse-

AAAACTTTGCCGAGTGTATCTGTC

2.2.3 Pancreatic differentiation from hPSC’s

In all differentiation assays, mutants were analyzed in parallel with isogenic WT controls.
hPSC’s were passaged onto 1:30 matrigel coated 6 well plates using TryplE and ROCK
inhibitor. Cells were fed with hPSC media every day until they reached ~90%
confluency. Pancreas differentiation was initiated on day 0 with RPMI media
supplemented with 3µM Chir99021 and 100µg/ml Activin A. On day 1 media was
changed to RPMI with 100µg/ml Activin A, 0.3µM Chir99021 and 5µg/ml bFGF. Day 2
was SFD with 100µg/ml Activin A. Cells were harvested on day 3 (DE stage) for flow
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cytometry analysis and RNA collection using 0.25% Trypsin for 5 minutes. From days 3
to 5 cells were fed with DMEM-F12 containing 0.25mM ascorbic acid, 50ng/ml FGF7 and
1.25µM IWP2. Day 6-8 media contained DMEM high glucose (5g/L) supplemented with
1:100 B27 without RA, 1X glutamax, 0.25mM ascorbic acid, 1:200 ITS-X, 50ng/ml FGF7,
0.5µM SANT-1, 1µM Retinoic Acid, 100nM LDN-193189 and 500nM Phorbol. For
experiments with SR1001, the RORα inverse agonist, 1µM of SR1001 was added to the
media from day 6-8. Cells were harvested on day 8 (PFG stage) for flow cytometry
analysis and RNA collection. Media for days 9-11 consisted of DMEM high glucose
(5g/L) supplemented with 1:100 B27 without RA, 1X glutamax, 0.25mM ascorbic acid,
1:200 ITS-X, 2ng/ml FGF7, 0.5µM SANT-1, 0.1µM Retinoic Acid, 200nM LDN-193189
and 250nM Phorbol. Cells were harvested on day 11 (PP stage) for flow cytometry
analysis and RNA collection. From days 12-14 the media was changed to MCDB131
supplemented with 20mM glucose, 2% FBS, 1X Glutamax, 1:200 ITS-X, 10ug/ml
Heparin, 10uM Zinc sulfate, 0.5µM SANT-1, 0.05µM Retinoic Acid, 200nM LDN-193189,
1µM T3 and 10µM ALK5i II. From day 14-28 cells were fed every other day with media
that contained MCDB131 with 20mM glucose, 2% FBS, 1X Glutamax, 1:200 ITS-X,
10ug/ml Heparin, 10uM Zinc sulfate, 200nM LDN-193189, 1µM T3, 10µM ALK5i II and
100nM GSIS XX. From day 29-40 cells were fed every other day after with media that
contained MCDB131 with 20mM glucose, 2% FBS, 1X Glutamax, 1:200 ITS-X, 10µg/ml
Heparin, 10uM Zinc sulfate, 1µM T3, 10µM ALK5i II, 1mM N-acetyl cysteine, 10µM
Trolox and 2µM R428. Cells were harvested on day 40 (β-like stage) for flow cytometry
analysis and RNA collection.
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2.2.4 Flow Cytometry

Single cell suspensions were prepared by treating cells with 0.25% Trypsin/EDTA for 3
to 5 minutes. For intracellular staining, cells were fixed with 1.6% paraformaldehyde
(Electron Microscopy Science) for 30 minutes at 37°C. Cells were washed,
permeabilized and stained with 1X saponin buffer (Biolegend). Primary antibodies were
diluted to the appropriate concentrations in 100uL of saponin buffer and cells were
stained for 30 minutes at room temperature. Samples were washed using 100uL
saponin twice and incubated for 30min using the appropriated secondary antibody.
Following the staining, cells were resuspended in FACS buffer (DPBS with 0.1% BSA
and 0.1% sodium azide). All samples were run on a FACSCantos II or Cytoflex flow
cytometer (Becton Dickinson) and analyzed using FlowJo (Treestar) software program.

2.2.5 RNA isolation and cDNA synthesis

Cells were lysed using Lysis buffer provided with the PureLink RNA Micro Kit (Invitrogen
Cat No 12183-016) and stored at -80c. To harvest RNA, samples were thawed out at 4c
and RNA was extracted using the PureLink RNA Micro Kit following the manufacturer’s
instructions. 14µl of RNAse free water was used to resuspend the isolated RNA. cDNA
was produced using the SuperScript™ III First-Strand Synthesis System kit (Invitrogen).
Quantitative PCR was carried out on a LightCycler 480 II with SYBR select master mix
(Invitrogen). For all experiments, TBP (Veazey and Golding, 2011) was used as a
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housekeeping gene to determine relative gene expression levels. Gene expression
levels were then divided by wild type levels for better graphical representation. All
primers used for qRTPCR are in Table 2-2.

Table 2-2. qRTPCR primers
Gene
CDX2

GATA4

GATA6

NKX6.1

PDX1

RORα

SOX2

TBP
R5rs12953985
ChIP-qPCR

Sequence 5’ to 3’
Forward- TCCTGGTCTGGGAAGGGAAGAGAAA
Reverse- CGGAAGCCAAAGGCAGCTAAGATAG
Forward- GCTGTGCTGTGGTGGGTTAAGT
Reverse- CGCCCTGCATCCCTAATACCAAATC
Forward- GAGGCTTGCTGAAAGAGTGAGAGAAGA
Reverse- TCCTAGTCCTGGCTTCTGGAAGTG
Forward- AGGACGACGACTACAATAAGCCTCTG
Reverse- CGCTGCTGGACTTGTGCTTCT
Forward- GCCGGCTCTTCAAAGACAATGGA
Reverse- GGTCGCCCGAGTAAGAATGGCTTTAT
Forward- TACCTGGACATACAGCCTTC
Reverse- CGTTGGTGAACGAACAGTAG
Forward- ATGACCAGCTCGCAGACCTACA
Reverse- GGACTTGACCACCGAACCCA
Forward- TTGCTGAGAAGAGTGTGCTGGAGATG
Reverse- CGTAAGGTGGCAGGCTGTTGTT
Forward- ACTTTAGAGATGGAAGAGACTTGAC
Reverse- CTAGCCCACAGCACCAAG
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PDX1

Forward- TATCCAGTCAGAGGCTGGTC

ChIP-qPCR

Reverse- CTGACTTAAACAGGGCCACTT

FOXN1

Forward- CAGGCAGGATAAAGGTTGGA

ChIP-qPCR

Reverse- TCTGGGACTTATGTGGAGAGG

SPARC

Forward- TTGGGCCTGGTTCTGCCCCT

ChIP-qPCR

Reverse- CCGGGGCTGCTGCCTAAACC

GATA4

Forward- CGCTGAGAGCACAGACAAT

ChIP-qPCR

Reverse- AGGGAGTGGGAAAGACCA

2.2.6 Immunofluorescence staining

At days 2, 7 and 10 of the differentiation, cells were harvested by incubating with 0.25%
Trypsin for 5 mins at 37c. These cells were spun down at 1200rpm for 3 mins in PBS
and plated onto 1:3 matrigel coated glass coverslips in the appropriate differentiation
media with 5 µM ROCK inhibitor. Cells were fixed the next day at DE (day 3), PFG (day
8) or PP (day 11) stages. For the NKX6.1 and SOX2 stains cells were fixed in 4% PFA in
PBS for 15 minutes at room temperature. For the RORα staining, cells were fixed at -20c
for 20 mins using cold methanol. Fixed cells were then washed 5-8 times with PBS on
ice. Fixed cells were blocked for one hour (5% normal goat serum, 0.3% TritonX-100 in
DPBS) and stained in primary antibody in staining buffer (1% BSA, 0.3% TritonX-100 in
DPBS) overnight at 4°C. After washing with 3 times PBS for 5 mins each, cells were
stained in secondary antibody in staining buffer for 2 hours at room temperature. After
washing with 3 times PBS for 5 mins each, cells were stained with Hoescth diluted in
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PBS for 15 mins. Slides were viewed under a Leica DMI 4000B microscope and digital
images were captured with Leica Application Suite software.

2.2.7 Enhancer cloning and luciferase reporter assays

The 3’ regulatory region, R5, was PCR amplified from genomic DNA of the Mel+/+ | G/G cell
line with Phusion High-Fidelity DNA Polymerase (New England BioLabs) (primers in
TableS2). These PCR products were cleaned up using NucleoSpin® Gel and PCR
Clean-up kit (Machery-nagel) and cloned into a pGL4.23[luc2/minP] vector backbone
(Promega) using In-FUSION HD. Correct cloning was assessed by Sanger sequencing
and restriction enzyme digestion. DNA was prepared with the HiSpeed Plasmid Maxi Kit
(Qiagen). At days 2 and 7 of the differentiation, cells were harvested by incubating with
0.25% Trypsin for 5 mins at 37c. These cells were spun down at 1200rpm for 3 mins in
PBS and plated onto 1:30 matrigel coated 12 well plates in the appropriate differentiation
media with 5 µM ROCK inhibitor. These cells were then transfected on the same day
with either 1ug of pGL4.23-R5 vector or empty pGL4.23 vector and 4ng of Renilla
normalizer control pGL4.75[hRluc/CMV] (Promega) using Lipofectamine Stem reagent
(Invitrogen) in Opti-MEM (Gibco) according to the manufacturer's' instructions.
Luciferase activity was measured 24 h after transfection (at the DE and PFG stages)
with the Dual-Luciferase Reporter Assay System (Promega). Firefly luciferase activity
was normalized to Renilla luciferase activity and then to the amount of empty
pGL4.23[luc2/minP] vector backbone.
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2.2.8 ChIP-qPCR

PP cells (1x107 cells) were harvested using 0.25% Trypsin and cross-linked in 1%
formaldehyde in PBS by shaking for 10 min at room temperature. The cross-linking
reaction was stopped by the addition of glycine to a final concentration of 125 mM and
shaking for 5 min at room temperature. Cross-linked cells were washed 3X with ice cold
PBS and pelleted by spinning at 2000rpm for 5 min at 4c. For chromatin fragmentation,
cells were resuspended in 1ml cell lysis buffer (10 mM Tris-HCl (pH 8.0), 10 mM NaCl,
0.2% NP-40) with fresh protease inhibitor and PMSF for 10 min on ice. Cells were spun
down and resuspended in 1ml nuclei lysis buffer (50mM Tris-HCL (pH 8.1), 10mM
EDTA, 1%SDS) with fresh protease inhibitor and PMSF and sonicated in a Covaris S220
sonicator with a duty cycle of 2%, a peak incident power of 105 W and 200 cycles per
burst for 20 min. The fragmented chromatin was diluted 1:2 in IP dilution buffer (20 mM
Tris-HCl (pH 8.1), 2 mM EDTA, 150mM NaCl, 1% Triton X-100, 0.01% SDS, Protease
Inhibitors) and directly used for immunoprecipitation. Samples were precleared with 5ug
IgG isotype, Protein G agarose beads for 2 hours at 4c. 180ul of the supernatant was
saved as Input DNA. The rest of the supernatant were split equally into 2 1ml tubes (5 X
106 cell each) for incubation with 10ug RORα or IgG control antibody. These antibodies
were pre bound to Protein G agarose beads overnight at 4c. Beads were then washed 5
times using (1.) IP wash 1(20mM Tris-HCL (Ph 8.1), 2mM EDTA, 50mM NaCl, 1% Triton
X-100, 0.1%SDS), (2 and 3.) High salt buffer (20mM Tris-HCL (Ph 8.1), 2mM EDTA,
500mM NaCl, 1% Triton X-100, 0.01%SDS), (3.) IP wash 2 (10mM Tris-HCL (Ph 8.1),
1mM EDTA, 0.25M LiCl, 1% NP-40, 1% deoxycholic acid), and (4 and 5.) TE buffer (10
mM Tris-HCl (pH 8.0), 1 mM EDTA). Subsequently, protein-DNA complexes were eluted
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from the beads in Elution-Buffer (100 mM NaHCO3 and 1% SDS) at 65c for 20 min.
Cross-links were reversed at 65c overnight and incubated with ProteinaseK and RNase
for 2 hours at 55c. DNA was extracted using 400 µl of phenol/chloroform/isoamyl alcohol
by vortexing then centrifuged at 14,000 rpm for 5 min at room temperature. The aqueous
layer containing pulled down genomic DNA was transferred to fresh 1.5 ml Eppendorf
tubes. 16uL of 5M NaCl, 1.5uL of 20mg/mL glycogen and 800µl of 100% ethanol were
added to the samples, which were then vortexed. The samples were next incubated
overnight at -20°C to precipitate the DNA. Precipitated DNA was pelleted by centrifuging
at 14,000 rpm for 30 min at 4°C. The DNA pellet was then washed with ice-cold 70%
ethanol and centrifuged at 14,000 rpm for 5 min at 4°C. The DNA was resuspended with
100ul TE buffer and 1.5ul was used for each qPCR reaction.

In order to identify positive control regions for the ChIP, we looked for RORα binding
motifs within active regulatory regions of known pancreas specific transcription factors,
such as GATA4, PDX1 and SOX9. We also tested gene expression of SPARC and
NR1D2 at the PFG stage. RORα has been demonstrated to bind to the regulatory
regions of SPARC and NR1D2 in HepG2 cells (Chauvet et al., 2011). We detected
RORα binding at the PFG stage in a previously described regulatory region of SPARC
as well as at a region proximal to GATA4 (Figure 3-9 D).
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2.2.9 Chipseq data analysis

Raw read fastq files for PDX1 ChIPseq (GSE58686 Teo et. al.), H3K4Me1, Input, HNF6,
FOXA2 and PDX1 ChIPseq (E-MATB-1990 Weedon et. al.) were downloaded. ATACseq raw read were downloaded from GSE114101 (Lee et al., 2019). Next, reads were
aligned to hg19 genome using bowtie2 (2.2.6) with only 1 mismatch allowed per read
and only 1 alignment per read. These sam files were converted to bam format using
samtools1.6. Next the bam files were converted to bedgraph format using
bedtools2.27.1. We used MACS2 for peak calling with a p value cut-off of 1e-5. These
peaks were verified by performing motif analysis using the findMotifsGenome.pl
command on HOMER. Bedgraph files for Input, H3K4Me1 and peaks for PDX1, HNF6
and FOXA2 were loaded onto Intergrative Genomic Viewer (IGV v2.3) for visualization.

2.2.10 Western Blot

PFG and PP cells (1x107 cells) were harvested using 0.25% Trypsin, washed twice with
PBS, pelleted and stored at -80c. Protein from cell pellet was quantified using Pierce™
BCA Protein Assay Kit (Thermo Fischer scientific, cat No. 23227). 20ug of protein was
loaded onto a 4-12% Bis-Tris SDS-polyacrylamide gel (Invitrogen). Samples were
transferred into a PVDF membrane (Thermo Fisher) and membrane blocking was
performed using 2% nonfat dry milk. The membrane was stained in primary antibody
diluted in 2% nonfat dry milk overnight at 4°C. After washing 3 times with 1X PBS-T for 5
mins each, the membrane was stained in secondary antibody diluted in 2% nonfat dry
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milk for 1 hour at room temperature. The membrane was washed 3 times with 1X PBS-T
for 5 mins each. HRP was detected using Pierce™ TMB Substrate Kit and membrane
was exposed to HyBlot CL autoradiography film (Denville Scientific) to visualize the
protein band.

2.2.11 SiRNA knockdown of RORα

Human RORα DsiRNAs (hs.Ri.RORA.13.2) and Scrambled negative control DsiRNA
were obtained from Integrated DNA Technologies (IDT) . At day6 of the differentiation,
cells were harvested by incubating with 0.25% Trypsin for 5 mins at 37c. These cells
were spun down at 1200rpm for 3 mins in PBS and plated onto 1:30 matrigel coated 12
well plates at a 1:1 ratio in the appropriate differentiation media with 5 µM ROCK
inhibitor. 10nM of the control scrambled siRNA or RORα siRNA (13.2) were added onto
these cells at the same time with Lipofectamine RNAi MAX (Invitrogen) following the
recommended procedure. SiRNAs were removed the next day by replacing with fresh
media. Transfected cells were harvested and examined for knockdown efficiency 48 hrs
after transfection (PFG stage) for RNA level by qRT-PCR and protein level by
immunofluorescence. Cells were also fixed for intracellular flow cytometry as described.
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2.3 QUANTIFICATION AND STATISTICAL ANALYSIS

Statistical analysis was performed using the GraphPad Prism software. The results are
expressed as the mean ± standard error of the mean. Ordinary one-way ANOVA with
multiple comparisons were used for statistics with correction for multiple comparisons
using statistical hypothesis testing perform using Tukey. An unpaired two-tailed
Student’s t-test with the assumption of same SD was performed for the enhancer
luciferase assays. An unpaired two-tailed Student’s t-test performed for the quantifying
c-peptide+ cells at the β-like stage. In figures * P<0.05, **P<0.01, ***P<0.001 and
****P<0.0001. Statistical analysis on the patient cohort data was performed using R. Chisquare and Fisher Exact probability tests were used to compare the frequency of the
minor allele of the SNP in different groups. Odds ratios were calculated to estimate the
risk of the minor allele A in the PA versus non PA groups.
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Table 2-3. Resources Table
REAGENT or RESOURCE

SOURCE

IDENTIFIER

Rabbit anti-GATA6

Cell Signaling
Technology

5851S

Biotinylated goat anti PDX1/IPF1

R&D Systems

BAF2419

Mouse IgG1 anti-NKX6.1

DSHB

F55A10

Rat anti-Somatostatin

Santa Cruz

sc-47706

Mouse IgG1 anti-Glucagon

Sigma-Aldrich

G2654-.2ML

Rabbit anti-SOX2

Cell Signaling
Technology

3579

Mouse IgG1 anti-SOX2

Biolegend

656102

Mouse IgG1 anti-SOX17

BD Pharmingen

561590

Rabbit anti-C-Peptide

Cell Signaling

4593S

Rabbit anti-CDX2

Abcam

ab76541

Hoechst 33342 solution

Thermo Fischer
Scientific

62249

Rabbit anti-ROR alpha

Abcam

ab60134

Goat anti-mouse IgG1-488

Jackson
Immunoresearch

115-545-205

Goat anti-mouse IgG1-PE

Jackson
Immunoresearch

115-115-205

Goat anti-mouse IgG1-647

Jackson
Immunoresearch

115-605-205

Goat anti-rabbit alexa 647

Invitrogen

A21245

Goat anti-rabbit IgG-PE

Jackson
Immunoresearch

111-116-144

Donkey anti-mouse IgG
alexa647

Jackson
Immunoresearch

715-605-150

Antibodies
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Donkey anti-rabbit IgG-PE

Jackson
Immunoresearch

711-116-152

Streptavidin, Pacific Blue
conjugate

Thermo Fischer
Scientific

S11222

Goat anti Rat alexa 647

Thermo Fischer
scientific

A21247

Chemicals, Peptides, and Recombinant Proteins
Iscove’s DMEM

Corning

10-016-CV

DMEM/F12

Corning

10-092-CV

2-β mercapthoethanol – 55mM

Invitrogen

21985023

NEAA – 10 mM

Invitrogen

11140050

Recombinant human bFGF

R & D Systems

233-FB/CF

Y-27632 (ROCK inhibitor)

R&D systems

1254/50

Fetal Bovine Serum

Tissue Culture
Biologicals

101

Knock-out Serum Replacement

Invitrogen

10828-028

TRYPLE Express w/ Phenol Red

Invitrogen

12605010

Pen/Strep 100X

Mediatech

MT30-002-CI

L-Glutamine

Mediatech

MT25-005-CI

Gelatin

Sigma

G1890

Activin A

R&D

CHIR99021

Tocris

4423

bFGF

Thermo Fischer
Scientific

PHG0263

FGF7

R&D

251-KG-050/CF

SANT-1

Sigma-Aldrich

S4572

Retinoic Acid

Sigma-Aldrich

R2625

LDN-193189

STEMGENT

04-0074
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Phorbol 12-myristate 13-acetate

Tocris

1201

Heparin

Sigma-Aldrich

H3149

T3 (250 mg)

Sigma-Aldrich

T6397

ALK5 inhibitor

Enzo Life Sciences

ALX-270-445

GSIXX

Calbiochem

565789

N-Acetyl-L-cysteine

Sigma-Aldrich

A9165

Trolox

EMD

648471

SR1001

Tocris

4868

R428

Selleck Chemicals

S2841

Dual-Luciferase® Reporter
Assay System

Promega

E1910

Invitrogen PureLink RNA Micro
Kit

Invitrogen

Gibson Assembly® Master Mix

NEB

E2611S

NucleoSpin® Gel and PCR
Clean-up

Machery-nagel

#740609.250

HiSpeed Plasmid Maxi Kit

Qiagen

12663

SuperScript™ III First-Strand
Synthesis System

Invitrogen

In-Fusion HD cloning kit

Clonetech

639647

Guide RNA’s, ssODN’s, primers
and siRNA’s

This thesis

Table 2-1

Primers for quantitative RT-PCR

This thesis

Table 2-2

Zinc Sulfate

Critical Commercial Assays

12183-016

18080051

Experimental Models: Cell Lines
Provided in Table1
Oligonucleotides
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Recombinant DNA
pGL4.23[luc2/minP]

Promega

E8411

pGL4.75[hRluc/CMV]

Promega

E6931

pCas9_GFP

Addgene

44719

gRNA empty vector

Addgene

41824

FlowJo

Ashland

GraphPad Prism

GraphPad Software

https://www.flowjo.com/so
lutions/flowjo/ downloads
https://www.graphpad.co
m/support/faqid/%201952

ApE plasmid Editor

M. Wayne Davis
http://biologylabs.utah.ed
u/jorgensen/wayned/ape/

Leica Application Suite X

Leica

Software and Algorithms

https://www.leicamicrosystems.com/products/micros
cope-software/details/product/leicalas-x-ls/

Bowtie2

http://bowtiebio.sourceforge.net/bowti
e2/index.shtml

Samtools 1.6

http://samtools.sourceforg
e.net/

Bedtools 2.27.1

https://bedtools.readthedo
cs.io/en/latest/

MACS2

http://liulab.dfci.harvard.e
du/MACS/

HOMER

http://homer.ucsd.edu/ho
mer/

Intergrative Genomic Viewer
(IGV v2.3)

http://software.broadinstit
ute.org/software/igv/

SnapGene

https://www.snapgene.co
m/
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CHAPTER 3:
THE PENETRANCE OF PANCREATIC AGENESIS CAUSED BY GATA6 MUTATIONS
IS MODIFIED BY A NON-CODING SNP

3.1 Introduction
Pancreatic agenesis (PA) is a rare disorder resulting from defective pancreatic
development. Clinically, PA can be complete or partial, but distinguishing between these
two possibilities can be difficult. For the purposes of this work, we are defining PA as
patients presenting with severe exocrine insufficiency and neonatal diabetes diagnosed
in the first 6 months of life. Isolated incidences of PA have been described as early as
1969, however the genetic causes of this disease were not unraveled until 1997, when a
homozygous mutation in PDX1 was identified as a cause (Dourov and Buyl-Strouvens,
1969; Stoffers et al., 1997). Since then, PTF1A, another key pancreatic transcription
factor has been implicated as a cause of PA (Sellick, Barker, Stolte-dijkstra, et al., 2004;
Concepcion et al., 2014; Shaw-Smith et al., 2014). More recently, haploinsufficiency of
GATA6, caused by heterozygous mutations, was shown to be the most common cause
of PA (Lango Allen et al., 2012). Interestingly, as is common with many disorders caused
by haploinsufficiency, patients with GATA6 heterozygous mutations display a large
phenotypic variability, with the pancreatic phenotype ranging from PA, to adult-onset
diabetes, to absence of diabetes even in adulthood ( Shaw-Smith et al., 2014; Shi et al.,
2017). In some cases, marked phenotypic variability has been observed even among
affected members of the same family (Yau et al., 2017). This phenotypic variability can
be stochastic, due to mosaicism in the case of de novo mutations, and/or resulting from
secondary disease-modifying genes that act in the GATA6 pathway during development
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(De Franco, Shaw-Smith, Sarah E Flanagan, et al., 2013; Shi et al., 2017; Tiyaboonchai
et al., 2017). Given the majority of known GATA6 mutations have been identified by
sequencing the coding region of the gene, another possible explanation for disease
penetrance could be differences in the non-coding region of the GATA6 locus that
regulate its expression during development (Rodríguez-Seguí, Akerman and Ferrer,
2012; Yorifuji et al., 2012; Catli et al., 2013; Suzuki et al., 2014; Yu et al., 2014; Christina
S. Chao et al., 2015; Stanescu et al., 2015).

The increasing importance of non-coding regions in development and disease have
been a fairly recent phenomenon (Zhang and Lupski, 2015). A rather surprising feature
of the fully sequenced and annotated human genome has been the unexpectedly high
proportion of functional regions of the genome. While only about 1.3% of the genome is
ascribed to coding regions, close to 40% of the human genome has been speculated to
have regulatory functions on tissue-specific gene expression (Heintzman et al., 2007;
Thurman et al., 2012; Gordon and Lyonnet, 2014). Thus studying non-coding variants
residing in these regulatory regions may play a pivotal role in understanding the
incomplete penetrance of haploinsufficiency related disorders (Mcclellan and King, 2010;
Brewer et al., 2014; Castel et al., 2018). Single nucleotide polymorphisms (SNPs) can
alter transcription factor binding at regulatory regions and hence have a major impact on
chromatin architecture and gene expression (Do et al., 2017; Chen et al., 2018). A
number of such SNPs have been identified by genome-wide association studies
(GWAS) to be associated with complex diseases (Visscher et al., 2017). However
mechanistic insights are limited due to the lack of adequate model systems to
understand how specific risk variants functionally contribute to the underlying
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pathogenesis (Mcclellan and King, 2010; Soldner et al., 2016). The advent of clustered
regularly interspaced short palindromic repeats (CRISPR)-CRISPR-associated 9 (Cas9)
gene editing has proven to be an invaluable tool to test the effect of disease modifying
SNPs on gene expression in specific tissue associated cell lines and diseases (Hsu,
Lander and Zhang, 2014; Chen et al., 2018; Wang et al., 2018). However, studies
testing the effect of SNPs on gene expression during embryonic development have been
limited (Soldner et al., 2016; Pashos et al., 2017).

Human pluripotent stem cells (hPSCs) present a great opportunity to study
developmental genetic disorders. The ability to have clonal populations and isogenic cell
lines, where only a single mutation or SNP differentiates two cell lines, makes them ideal
for teasing out the function of a given genomic change on development and disease
(Musunuru, 2013). As our fundamental knowledge of developmental pathways expand,
the increasing number of in vitro differentiation protocols to generate various cell types
from hPSCs has grown considerably. Furthermore, in diseases such as PA, mouse
models do not completely phenocopy the human disease. In fact, the loss of three or
more alleles of Gata6 and Gata4, the two major GATA family members expressed
during pancreas specification, are needed for mice to mimic the human phenotype
(Koutsourakis et al., 1999; Zhao et al., 2005; Carrasco et al., 2012; Xuan et al., 2012).
Using directed differentiation protocols to model pancreas development from hPSCs, it
has been shown that GATA6 haploinsufficiency leads to a defect in generating pancreas
progenitors and fewer pancreatic endocrine cells (Shi et al., 2017; Tiyaboonchai et al.,
2017).
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In this study, we investigated the role of the non-coding SNP rs12953985, which lies
approximately 8kb downstream of the GATA6 gene. We found that the minor allele
variant (A) was enriched in a cohort of 33 total patients with pancreatic agenesis caused
by GATA6 mutations. Using CRISPR-CAS9 genome editing, we analyze the effect of
this variant on GATA6 expression during in vitro pancreas differentiation from multiple
genetically matched hPSC lines. We find that the minor allele variant of rs12953985, in
conjunction with a GATA6 heterozygous mutation, leads to the largest reduction in
GATA6 protein expression specifically during pancreas specification and a more severe
defect in generating pancreatic progenitors. We also determine that the minor allele
variant of this SNP impairs retinoic acid receptor-related orphan receptor α (RORα)
binding by chromatin immune-precipitation (ChIP) assay. Inhibiting the function of RORα
using an inverse agonist decreases GATA6 expression and inhibits pancreas
development. This effect is observed only in lines with an intact RORα binding site
supplied by the major allele variant of the SNP. Finally, we modify the minor allele
variant of the SNP to a consensus RORα binding site in the GATA6 PA patient induced
pluripotent stem cell (iPSC) line. We find that the iPSC line where both the coding
mutation was corrected and the RORα binding site is introduced has the highest levels
of GATA6 expression and most efficient pancreas differentiation capacity. Our study
identifies a possible genetic modifier contributing to the pancreatic agenesis phenotype
in patients with GATA6 mutations and provides insights into RORα as a regulator of
pancreas development in humans.
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3.2 Results

3.2.1 GATA6 haploinsufficiency leads to a pancreas progenitor defect and a
switch in cell fate

In recent years, in vitro pancreas differentiation protocols to generate β-like cells from
hPSCs have become well established (Pagliuca et al., 2014; Rezania et al., 2014; M.
Cristina Nostro et al., 2015). These protocols leverage existing knowledge of
developmental pathways to guide hPSCs through defined stages of development such
as the SOX17+ definitive endoderm (DE), PDX1+ posterior foregut (PFG) and
PDX1+/NKX6.1+ pancreas progenitor (PP) stages (Figure 3-1 A). Previous studies have
shown that pancreas progenitors marked by PDX1 and NKX6.1 give rise to endocrine,
ductal and acinar lineages in humans (Jennings et al., 2013, 2015b). Given that a large
proportion of patients with GATA6 heterozygous mutations are born with minimal to no
pancreatic tissue, a defect in generating pancreas progenitors is expected. Recently,
studies using genome edited embryonic stem cell (ESC) lines have shown that
heterozygous mutations in GATA6 lead to a defect at the pancreas progenitor (PP)
stage (Shi et al., 2017). However, given the variability in the types and locations of
mutations in GATA6, the use of iPSC lines derived from PA patients can aid in
understanding the effects of different mutations. We used a previously described PA
patient iPSC line (denoted as iPS+/mut) to verify whether that particular GATA6 mutation
leads to the same phenotype at the PP stage (Stanescu et al., 2015; Tiyaboonchai et al.,
2017). This patient has a heterozygous 4 base pair duplication (c.dup606-609) in exon 2
of GATA6 that leads to a premature STOP codon and a truncated protein (Figure 3-2 A)
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(Stanescu et al., 2015). This mutation was previously corrected using CRISPR-CAS9
and used as a genetically matched control (denoted as iPS+/+) (Tiyaboonchai et al.,
2017). We also generated an identical mutation in an ESC line (denoted as Mel+/mut) to
compare the effect of this mutation on two different genetic backgrounds (Figure 3-2 A,
B and Table 3-1). We used flow cytometry to measure GATA6 protein levels compared
to isotype controls and to measure PDX1+ and NKX6.1+ cells at the DE, PFG and PP
stages of the differentiation. As expected, we found that all the lines differentiated
normally to the PFG stage marked by the percent PDX1+ cells (Figure 3-1 B). By gating
on PDX1+ cells at the PP stage, we identified that the mutant cells lines (iPS+/mut and
Mel+/mut) generated fewer PDX1+/NKX6.1+ PP cells compared to their genetically
identical wild type controls (iPS+/+ and Mel+/+) (Figure 3-1 C, D and Figure 3-2 D). The
mutant cells lines also had lower GATA6 protein levels at the PFG and PP stages of the
differentiation (Figure 3-1 G).

The defect in generating NKX6.1+ cells at the PP stage could be due to multiple
reasons, including increased apoptosis or a switch in the cell fate of the PDX1+ cells
caused by GATA6 haploinsufficiency. It has been previously shown that GATA6
heterozygous mutants cause no significant apoptosis or proliferation defects at the PP
stage (Shi et al., 2017). Interestingly, in mouse models of PA, there is extension of the
SOX2+ stomach and CDX2+ intestinal domains into the pancreatic domain (Xuan and
Sussel, 2016). To identify any switches in the cell fate at the PP stage caused by the
GATA6 mutation, we measured SOX2+ and CDX2+ cells in the PDX1+ population
(Figure 3-2 D and E). We found that the reduced GATA6 levels in the mutant lines at
PFG and PP stages leads to a decrease in the NKX6.1+ cells and an increase in SOX2+
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cells at the PP stage (Figure 3-1 C, D and E). We detected no SOX2 or CDX2
expression at the PFG stage. We did not detect CDX2 protein during any stage of the
differentiation (Figure 3-2 E).
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Figure 3-1: GATA6 haploinsufficiency leads to a pancreas progenitor defect and a switch in
cell fate
(A) Schematic of pancreas differentiation protocol from hPSCs. The cell types and key markers at
each stage are shown. hPS, undifferentiated hPSC stage; DE, definitive endoderm stage; PFG,
posterior foregut stage; PP, pancreas progenitor stage; β, β-like cells stage.
(B-H) Data from Mel+/+, Mel+/mut, iPS+/+ and iPS+/mut cell lines.
(B) Flow cytometry quantification of %PDX1+ cells at the PFG stage.
(C) Representative flow cytometry dot plot for SOX2 and NKX6.1 co-staining gated on PDX1+ cells
at the PP stage.
(D-E) Flow cytometry quantification at the PP stage. (D) %PDX1+/NKX6.1+ double positive cells
and (E) %PDX1+/SOX2+ double positive cells.
(F) Representative flow cytometry histograms for GATA6 compared to Isotype control at the DE,
PFG and PP stages for the Mel+/+ and iPS+/+ cell lines.
(G) Mean fluorescence Intensity (MFI) of GATA6 relative to MFI of Isotype at the DE, PFG and PP
stages.
(H) qRT-PCR analysis of key pancreatic and stomach development genes relative to the
housekeeping gene TBP and normalized to Mel+/+ at the PP stage (n = 4).
All data represented as Mean +/- SEM. Ordinary one-way ANOVA with multiple comparisons were
used for statistics. *pvalue <0.05, **pvalue <0.01, ***pvalue <0.001, ****pvalue <0.0001.

A second interesting observation from these studies was that the patient iPS+/+ line
generated PDX1+/NKX6.1+ PP cells with far less efficiency compared to the Mel+/+ line
(31 +/- 3 % vs. 60 +/- 4 %). In fact, the iPS+/+ line had a similar efficiency to the Mel+/mut
line (28 +/- 2 %) and the iPS+/mut line had much lower efficiency (10 +/- 6 %) (Figure 3-1
C, D and Table 3-2). While it is not surprising that different cell lines have different
baseline efficiencies of differentiation, we found that GATA6 protein levels in the iPS+/+
and Mel+/+ lines were identical at the DE stage. However, at the PFG and PP stages,
GATA6 protein levels in the iPS+/+ line was statistically lower by ~30% compared to the
Mel+/+ line (Figure 3-1 F, G and Table 3-3). Similar to the impacts on PP development,
GATA6 protein levels were comparable between the iPS+/+ and the Mel+/mut lines with the
iPS+/mut line being much lower (Figure 3-1 G and Table 3-2). We also measured RNA
levels of GATA4, a gene that is regulated by GATA6 specifically during human pancreas
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development, and found a reduction in levels similar to GATA6 (Figure 3-1 H)
(Lorberbaum and Sussel, 2017; Tiyaboonchai et al., 2017). RNA expression of GATA6,
NKX6.1 and PDX1 showed the same results as the protein expression of these genes
(Figure 3-1 H). Other pancreas specific genes such as MNX1, PTF1A, NKX2.2, ISL1,
NGN3 and NEUROD1 were also found to be downregulated in a similar manner to
GATA6. SOX2 and IRX2, genes involved in stomach development, were found to be
upregulated with lower levels of GATA6 (Figure 3-1 H). These data suggest that the
patient PA iPS cell line may carry an additional disease modifier that regulates GATA6
expression specifically during pancreas specification.
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Figure 3-2: Generating Mel1 ES cell lines
(A) CRISPR-CAS9 strategy to generate the GATA6 heterozygous mutation in the Mel ES cell
background. The green line marks the guide RNA sequence used. The nucleotides highlighted in
orange represent silent mutations incorporated into the ssODN. The nucleotides in red represent
the 4 base pair duplication. The amino acids highlighted in blue represent the 15 amino acids that
are different between the Mel+/mut and the iPS+/mut cell lines. The * represents the premature
STOP codon.
(B) Sequencing reads confirming the introduction of the heterozygous coding region mutations and
minor allele variant of rs12953985 in isogenic cell lines.
(C) Karyotypes for the Mel+/+ | G/G, Mel+/+ | A/A, Mel+/mut | G/G, Mel+/mut | A/A cell lines.
(D) Flow cytometry gating strategy for generating the NKX6.1+ and SOX2+ dot plots, PDX1+/
NKX6.1+ and the PDX1/ SOX2+ graphs.
(E) Flow cytometry dot plots for NKX6.1 and CDX2 co-staining at the PP stage for the Mel+/+ and
Mel+/mut cell lines.

3.2.2 The PA patient iPSCs have the minor allele variant of SNP rs12953985

The finding that GATA6 expression was lower in PA patient-derived pancreatic
progenitors even when the coding mutation was corrected was particularly interesting
because not all patients with GATA6 heterozygous mutations have PA. All previously
described GATA6 mutations have been identified either by exome sequencing or by
amplifying the exons, exon/intron boundaries and small portions of 3’ and 5’ UTR’s of
GATA6 followed by Sanger sequencing. Therefore, we hypothesized that a variant in a
non-coding regulatory region of GATA6 could act in conjunction with a coding mutation
resulting in a stronger phenotype. To identify active regulatory regions around GATA6,
we used a combination of three strategies. First, we identified regions enriched for
H3K4Me1 at the PP stage in a 200kb window surrounding GATA6 using previously
published data (Figure 3-3 A) (Weedon, Ines Cebola, et al., 2014). Second, using
previously published datasets we identified transcription factor binding regions for PDX1,
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HNF6 and FOXA2 that are known regulators of pancreas development at the PP stage
(Figure 3-3 A) (Weedon, Ines Cebola, et al., 2014; Teo et al., 2015). Third, we analyzed
H3K4Me1, H3K27Ac and DNAse hypersensitivity sites from the Roadmap Epigenetics
Consortium (REMC) in fetal human tissues that arise from the gut tube, proximal to the
pancreas, such as the small and large intestine, stomach and adult liver (Figure 3-3 B)
(Consortium et al., 2015). These strategies narrowed our search to regions enriched for
H3K4Me1 and that bind at least two of the three transcription factors.

Upon sequencing these regions, the only difference we discovered between the patient
iPSC line and the Mel1 line was within a 3’ region ~8kb downstream of GATA6
(designated R5) (Figure 3-3 C). The patient iPS cell line was homozygous for the minor
allele A of the SNP rs12953985 and the Mel1 line was homozygous for the major allele
G variant (Figure 3-3 C). We cloned the entire R5 region into the pGL4.23 vector and
performed enhancer luciferase assays at the DE and PFG stages of differentiation. This
region showed luciferase activity over the empty pGL4.23 vector control at the PFG
stage, but not the DE stage (Figure 3-3 D). Recently published ATAC-seq data also
show that the chromatin in region R5 is accessible only during the PFG stage but not
during earlier stages of the differentiation (Figure 3-3 E) (Lee et al., 2019). Furthermore,
the homozygous minor allele variant of rs12953985 correlated with lower GATA6 RNA
levels in the pituitary and testis when analyzed on GtexEQTL (Figure 3-3 F).
Interestingly, this region is conserved in primates but not in rodents, which is consistent
with the differences in regulation of GATA6 during human pancreas development
compared to mice (Figure 3-3 H).
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R5

Figure 3-3: Identifying regulatory regions of GATA6
(A) Integrative Genomics Viewer (IGV) snapshot of chr18: 19649618-19836096 on hg19.
Bedgraph tracks for Input, H3K4Me1 and MACS peaks for PDX1, HNF6 and FOXA2 are plotted.
Below: Schematic of the GATA6 locus including exons (solid blue boxes), Untranslated regions
(hollow blue boxes), regions with H3K4Me1 enrichment with at least 2 transcription factors bound
(red boxes labeled R1 to R6).
(B) WashU epigenome browser snapshot of chr18: 19649618-19836096 on hg19. Bigwig tracks for
H3K4Me1, H3K27Ac and DNase hypersensitivity sites from fetal small intestine, fetal large
intestine, fetal stomach and adult liver are shown. The black boxes indicate regions R1-R6.
(C) Sequencing data from the CHOP.Panagenesis1 patient iPS line and Mel ES cell line for
rs12953985.
(D) Enhancer luciferase assays at the DE and PFG stages for R5. All values are nomalized to
renilla luciferase to control for transfection efficiency and then to the pGL4.23 empty vector
transfection. Unpaired t-test with two-tailed distribution was used to determine the significance.
(E) IGV snapshot of R5 showing ATAC-seq tracks from Lee et al. at hPS, DE, Day 5 and PFG
stages of the differentiation.
(F) GTEx eQTL plots for rs12953985 variant effect on GATA6 expression in pituitary and testis.
(G) CRISPR-CAS9 strategy to generate the minor allele variant of rs12953985 in the Mel+/+ | G/G
and Mel+/mut | G/G background. The green line marks the guide RNA sequence used.
(H) Multiz Alignments from UCSC genome browser for human, rhesus, mouse, dog, elephant,
chicken, x.tropicalis and zebrafish. The red highlight represents region R5.

3.2.3 The minor allele frequency of the SNP rs12953985 is enriched in PA patients

To confirm this finding in a larger PA patient cohort, we first tested the SNP in 4 patients
with PA caused by GATA6 mutations referred to the University of Chicago monogenic
diabetes registry for genetic testing (Figure 3-3 A and Table 3-4). We sequenced the
DNA of the 4 PA patients for rs12953985 and found that all carried the minor allele; 2
were heterozygous A/G and 2 were homozygous A/A for the minor allele variant. The
overall allele frequency in this group was 75% [95%CI=24.5%] (Figure 3-4 A and Table
3-4). We also sequenced eight wild type hPSC lines for rs12953985 and six of them
were homozygous G/G for the major allele while only two were heterozygous A/G
(Figure 3-5 B). We found no homozygous A/A minor allele variants. These findings
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suggest that rs12953985 may be a disease modifying SNP that can regulate GATA6
expression.
Figure 3-4: The minor allele frequency of SNP rs12953985 is higher in PA patients
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Figure 3-4: The minor allele frequency of SNP rs12953985 is higher in PA patients
(A) rs12953985 minor allele frequency in individuals with PA from the Chicago, Exeter and
combined cohorts compared to GnomAD European database. Plots show the frequency of the
minor allele A and the 95% confidence intervals.
(B) 4 pedigrees from the Exeter cohort, where the GATA6 mutation was inherited from a parent
with a mild or no pancreatic phenotype and the minor allele variant of the SNP was inherited in
trans from the other parent. Colors indicate phenotype of the patients as follows: Black, PA; Red,
Heart Defects; Grey, Adult-onset diabetes; Olive, Small pancreas with normal islets.
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Figure 3-5: Sequencing patient and wild type lines for rs12953985 variant
(A) Reference sequence and sequencing results for 5 PA patient samples from the Chicago cohort
described in Table S5.
(B) Reference sequence and sequencing results for 8 wild type hPSC lines.
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We sought to replicate these findings in a cohort of 36 patients of European ancestry (28
with PA, 2 with transient neonatal diabetes, 4 with diabetes diagnosed in adulthood, and
2 with congenital heart defects but no diabetes) heterozygous for GATA6 mutations
referred to the Exeter Molecular Genetics laboratory (Table 3-4). The minor allele, A,
was again found to be more frequent among patients with PA compared to the non-PA
group (allele frequency 42.3% [95%CI=13%] vs 22.2% [95%CI=19.2%]) (Figure 3-4 A
and Table 3-4). The A allele was present in 25/33 individuals with GATA6 PA tested in
the two cohorts for a cumulative allele frequency of 48.5% [95%CI=11.9%] (Figure 3-4 A
and Table 3-4). This is higher than the allele frequency among patients with the GATA6
mutation without PA (27.8% [95%CI=20.7%]) and the frequency among Europeans in
the GnomAD database (33.5% [95%CI=0.75%], ChiSquare p= 0.013) (Figure 3-4 A).

Phasing of the GATA6 mutation and the A allele of the SNP in 10 families (8
homozygotes AA and two heterozygotes GA with an inherited GATA6 mutation) showed
that the A variant was on the opposite allele of the mutation in 7 cases with PA and only
one case without PA (diagnosed with diabetes at 12 years) (Table 3-4). Interestingly, in
four pedigrees with multiple individuals harboring GATA6 mutations, the A allele was in
trans with the coding mutation in all the probands with PA while 4 family members
without PA either carried the A allele in cis with the coding mutation or were
homozygous GG (Figure 3-4 B). The most recent pregnancy for Family Exeter_04
carried a pathogenic GATA6 mutation and was homozygous GG for the SNP. Severe
congenital heart defects were detected prenatally leading to a termination of pregnancy.
At post-mortem the fetus was found to have a small pancreas with normal islet
architecture (Yau et al., 2017). The severity of the pancreatic phenotype in this individual
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is therefore impossible to assess. The Odds Ratio for carrying the A allele in trans with
the mutation suggested that this allele strongly increases the risk of pancreatic agenesis
[OR=7.78, 95%CI=0.8-76.1], however replication in larger PA and non-PA cohorts is
needed in order to confirm this result.

These results suggest the SNP A allele is

associated with PA and that it is usually found in trans with the coding mutation. These
data are consistent with the hypothesis that the SNP A allele when present on the only
functional coding allele of GATA6 will lower expression below a threshold required for
proper pancreas development.

3.2.4 The minor allele variant of rs12953985 lowers GATA6 expression during
pancreas specification

In order to add functional evidence that this SNP influences GATA6 expression and
pancreas development, we introduced the minor allele variant of the SNP, rs12953985,
into the Mel+/+ and Mel+/mut cell lines using CRISPR-CAS9 technology (Figure 3-3 G). We
differentiated the four genetically matched cell lines, Mel+/+ | G/G, Mel+/mut | G/G, Mel+/+ | A/A
and Mel+/mut | A/A (Table 3-1), to measure GATA6 protein levels at the DE, PFG and PP
stages and to measure the efficiency of PDX1+/NKX6.1+ cell generation at the PP
stage. The Mel+/+

| G/G

had the highest GATA6 expression at the PFG and PP stages

(Figures 3-6 A, B and Table 3-3).
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Figure 3-6: The minor allele variant of rs12953985 affects pancreas development
(A-J) Data from Mel+/+ | G/G, Mel+/+ | A/A, Mel+/mut | G/G, Mel+/mut | A/A cell lines.
(A) Representative flow cytometry histograms for GATA6 compared to Isotype control at the PFG
stage.
(B) Mean fluorescence Intensity (MFI) of GATA6 relative to MFI of Isotype at the DE, PFG and PP
stages.
(C) Flow cytometry quantification of %PDX1+ cells at the PFG stage.
(D) Representative flow cytometry dot plot for SOX2 and NKX6.1 co-staining at the PP stage.
(E-F) Flow cytometry quantification at the PP stage. (E) %PDX1+/NKX6.1+ double positive cells
and (F) %PDX1+/SOX2+ double positive cells.
(G) qRT-PCR analysis of key pancreatic and stomach development genes relative to the
housekeeping gene TBP and normalized to Mel+/+ | G/G at the PP stage.
(H) Representative flow cytometry dot plot for C-peptide and forward scatter (FSC) at the β stage.
(I) Quantification of %C-peptide+ cells at the β-like stage. Unpaired two-tailed t-tests were used for
statistics. *pvalue <0.05, **pvalue <0.01, ***pvalue <0.001.
(J) qRT-PCR analysis of key pancreatic β cell and islet signature genes relative to the
housekeeping gene TBP and normalized to Mel+/+ | G/G at the β-like stage.
All data represented as Mean +/- SEM. Ordinary one-way ANOVA with multiple comparisons were
used for statistics. *pvalue <0.05, **pvalue <0.01, ***pvalue <0.001, ****pvalue <0.0001.

Both, the Mel+/mut | G/G and Mel+/+ | A/A lines, showed ~25% reduction in GATA6 expression
while the Mel+/mut | A/A had the lowest GATA6 expression, ~50% reduction, compared to
the Mel+/+

| G/G

line at the PFG and PP stages (Figures 3-6 A, B and Table 3-3). This

reduction in GATA6 protein expression was also verified by western blot analyses at the
PFG and PP stages (Figure 3-7 A). The consequence of this reduction in GATA6
expression was seen at the PP stage in the efficiency of generating NKX6.1+ cells or
SOX2+ cells (Figures 3-6 C, D, E, F and Table 3-4). The Mel+/+ | G/G line had the highest
efficiency of generating NKX6.1+ cells and the lowest efficiency of generating SOX2+
cells at the PP stage (60 +/- 3 % and 6 +/- 2 % respectively). The Mel+/+

| A/A

and the

Mel+/mut | G/G lines had a lower efficiency of generating NKX6.1+ cells and concurrently an
increase in SOX2+ cells. The Mel+/mut | A/A line generated the fewest NKX6.1+ cells and
the most SOX2+ cells at the PP stage (22 +/- 4 % and 26 +/- 2 % respectively). These
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results were also verified using immunofluorescence (Figure 3-7 B). RNA expression of
key pancreatic genes GATA4, SOX2, NKX6.1, PDX1, MNX1, PTF1A, NKX2.2, ISL1,
NGN3 and NEUROD1, were lower in the lines with lower GATA6 expression (Figure 3-6
G). Conversely, SOX2 and IRX2 RNA expression were higher in these lines suggesting
a switch in the cell fate of PDX1+ cells at the PP stage (Figure 3-6 G). Previous studies
have shown that GATA6 heterozygous mutations lead to defects in generating C-peptide
positive cells at the β-like cell stage (Shi et al., 2017; Tiyaboonchai et al., 2017). To
confirm this, all four lines were differentiated to the β-like cell stage and CPEP+ cells
were measured. As expected, CPEP+ cells from the Mel+/mut

| G/G

line were reduced

compared to the CPEP+ cells from the Mel+/+ | G/G line (9 +/- 1% vs. 33 +/- 11%)(Figures
3-6 H and I). The minor allele variant line harboring the coding mutation (Mel+/mut

| A/A

)

demonstrated a statistically significant decrease in CPEP+ cells compared to its major
allele variant counterpart (Mel+/mut

| G/G

)(Figures 3-6 H and I). This decrease in CPEP+

cells was more pronounced in the CHOPWT6 genetic background (Figures 3-8 I and J).
We also detected a decrease in the percentage of SST+ and GCG+ cells at this stage
(Figures 3-7 C and D). The expression of key β cell genes, islet hormone genes and
genes related to β cell functionality were also lower in the lines with lower GATA6 levels
(Figure 3-6 J). These experiments were also replicated using cells of a different genetic
background (CHOPWT6 iPS) with similar results (Figure 3-8).
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Figure 3-7: Testing the effect of rs12953985 on isogenic Mel ES cell lines
(A) Western blot for GATA6 and loading control β Actin at the PFG and PP stages in the Mel+/+ | G/G,
Mel+/+ | A/A, Mel+/mut | G/G, Mel+/mut | A/A cell lines. Lanes 1 and 5 represent the Mel+/+ | G/G at the PFG
and PP stages respectively; Lanes 2 and 6 represent the Mel+/+ | A/A at the PFG and PP stages
respectively; Lanes 3 and 7 represent the Mel+/mut | G/G at the PFG and PP stages respectively;
Lanes 4 and 8 represent the Mel+/mut | A/A at the PFG and PP stages respectively.
(B) Immunofluorescence images at the PP stage for NKX6.1 in green, SOX2 in red and HOECHST
DNA stain in blue. Scale bar 200um.
(C) Representative flow cytometry dot plot for SST and GCG co-staining at the β-like stage.
(D) Flow cytometry quantification of SST+, GCG+ and SST+/ GCG+ double positive cells at β-like
stage.
All data is represented as Mean+/- SEM. Ordinary one-way ANOVA with multiple comparisons
were used for statistics. *pvalue <0.05, **pvalue <0.01, ***pvalue <0.001, ****pvalue <0.0001.

3.2.5 The minor allele variant of rs12953985 disrupts RORα binding

To determine if the minor allele variant of rs12953985 disrupted any transcription factor
binding sites, we used CIS-BP (Weirauch et al., 2014). We identified a RORα binding
domain that could potentially be disrupted by the G>A variant (Figure 3-9 A). Recent
bioinformatics data have suggested a possible role for RORα in human pancreas
development (Jennings et al., 2017). To detect RORα expression during the in vitro
differentiation protocol, qRT-PCR and immunofluorescence were performed at the DE,
PFG and PP stages (Figure 3-9 B and C). Robust RNA expression was detected at the
DE stage with slightly lower expression at the PFG and PP stages (Figure 3-9 B).
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Figure 3-8: Testing the effect of rs12953985 on isogenic CHOPWT6 iPS cell lines
(A-L) Data from Chopwt6+/+ | G/G, Chopwt6+/+ | A/A, Chopwt6+/mut | G/G, Chopwt6+/mut | A/A cell lines.
(A) Representative flow cytometry histograms for GATA6 compared to Isotype control at the PFG
stage.
(B) Mean fluorescence Intensity (MFI) of GATA6 relative to MFI of Isotype at the DE, PFG and PP
stages.
(C) Western blot for GATA6 and loading control β Actin at the PFG and PP stages. Lanes 1 and 5
represent the Chopwt6+/+ | G/G at the PFG and PP stages respectively; Lanes 2 and 6 represent the
Chopwt6+/+ | A/A at the PFG and PP stages respectively; Lanes 3 and 7 represent the Chopwt6+/mut |
G/G at the PFG and PP stages respectively; Lanes 4 and 8 represent the Chopwt6+/mut | A/A at the
PFG and PP stages respectively.
(D) Representative flow cytometry dot plot for SOX2 and NKX6.1 co-staining at the PP stage.
(E-G) Flow cytometry quantification of (E) %PDX1+ cells at the PFG stage (F) %PDX1+/NKX6.1+
double positive cells at the PP stage and (G) %PDX1+/SOX2+ double positive cells at the PP
stage.
(H) qRT-PCR analysis of key pancreatic and stomach development genes relative to the
housekeeping gene TBP and normalized to Chopwt6+/+ | G/G at the PP stage.
(I) Representative flow cytometry dot plot for C-peptide and forward scatter (FSC) at the β stage.
(J) Quantification of %C-peptide+ cells at the β-like stage. Unpaired two-tailed t-tests were used for
statistics. *pvalue <0.05, **pvalue <0.01, ***pvalue <0.001.
(K) Representative flow cytometry dot plot for SST and GCG co-staining at the β-like stage.
(L) Flow cytometry quantification of SST+, GCG+ and SST+/ GCG+ double positive cells at β-like
stage.
All data is represented as Mean+/- SEM. Ordinary one-way ANOVA with multiple comparisons
were used for statistics. *pvalue <0.05, **pvalue <0.01, ***pvalue <0.001, ****pvalue <0.0001.

We also did not detect expression of other ROR family members, RORB and RORC
(Figure 3-9 B and data not shown). Immunofluorescence showed RORα protein
expression at both DE and PFG stages (Figure 3-9 C). To determine RORα binding
efficiency in the presence of the G or A variant, ChIP-qPCR was performed on all four
lines at the PFG stage (Figure 3-9 D). The lines with the minor allele variant bound
RORα with lower efficiency compared to the major allele variant controls. At rs12953985,
we detected RORα binding in both Mel+/+ | G/G and the Mel+/mut | G/G lines over IgG control
(2.9 +/- 0.2 and 2.8 +/- 0.6 respectively). However, in the Mel+/+ | A/A and the Mel+/mut | A/A
lines, RORα binding was significantly reduced (1.7 +/- 0.2 and 1.4 +/- 0.4 respectively).
RORα binding was unaffected at positive and negative control regions in all four lines
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regardless of the GATA6 mutation or rs12953985 variant (Figure 3-9 D). These findings
suggest that RORα binds at the 3’ regulatory region, R5, specifically in the presence of
the major allele G variant of rs12953985.
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Figure 3-9: RORα regulates GATA6 during pancreas development
(A) Sequence of R5 around rs12953985 (nucleotide in red) and the consensus RORα binding motif
from JASPAR.
(B) qRT-PCR analysis of RORA and RORB relative to the housekeeping gene TBP at the DE, PFG
and PP stages in the Mel+/+ | G/G cell line.
(C) Immunofluorescence images for cells stained with RORα (red) and Hoechst (blue) at the DE
and PFG stages in the Mel+/+ | G/G cell line.
(D) ChIP-qRTPCR for RORα normalized to IgG control at R5 around rs12953985 and regulatory
regions of PDX1, FOXN1, SPARC and GATA4 at the PFG stage for the Mel+/+ | G/G, Mel+/+ | A/A, Mel+/
mut | G/G, Mel+/mut | A/A cell lines.
(E) Schematic of pancreas differentiation protocol from hPSCs. 1uM SR1001 was added for 2 days
before the PFG stage.
(F-J) Data from Mel+/+ | G/G and Mel+/+ | A/A cell lines treated with DMSO or SR1001.
(F) Representative flow cytometry histograms for GATA6 compared to Isotype control at the PFG
stage.
(G) Mean fluorescence Intensity (MFI) of GATA6 relative to MFI of Isotype at the PFG and PP
stages.
(H) Representative flow cytometry dot plot for SOX2 and NKX6.1 co-staining at the PP stage.
(I) Quantification of %PDX1+/NKX6.1+ double positive cells at the PP stage.
(J) Quantification of %PDX1+/SOX2+ double positive cells at the PP stage.
All data represented as Mean +/- SEM. Ordinary one-way ANOVA with multiple comparisons were
used for statistics. *pvalue <0.05, **pvalue <0.01, ***pvalue <0.001, ****pvalue <0.0001.

3.2.6

Inhibiting

RORα

during

pancreas

specification

disrupts

pancreas

differentiation

Next, we used a known inverse agonist of RORα, SR1001, during PFG specification
(Figure 3-9 E). SR1001 binds to the ligand binding domain of RORα and specifically
represses activity of genes that RORα activates in the absence of any ligand (Solt and
Burris, 2012). We hypothesized that SR1001 should selectively reduce GATA6
expression only in the presence of the major allele G variant of rs12953985. Since the
minor allele A variant disrupts RORα binding, SR1001 should have no further effect on
reducing GATA6 expression. We added SR1001 for 48 hours prior to the PFG stage and
measured GATA6 levels at the PFG and PP stages. We found a significant reduction in
GATA6 protein expression at the PFG stage in the line with the G allele while the line
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with the A allele was unaffected (Figures 3-9 F, G and Table 3-2). The consequence of
this reduction in GATA6 levels at the PFG stage were seen in the efficiency of
generating PDX1+/NKX6.1+ cells at the PP stage. The SR1001 treated cultures led to a
decrease in NKX6.1+ cells compared to dimethyl sulfoxide (DMSO) controls specifically
in the Mel+/+ | G/G line (35 +/- 10 % and 53 +/- 10 % respectively) (Figures 3-9 H, I and
Table 3-3). These experiments were replicated with similar results in the CHOPWT6
background (Figure 3-10).
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Figure 3-10: RORα regulates GATA6 in isogenic CHOPWT6 iPS cell lines
(A-E) Data from Chopwt6+/+ | G/G and Chopwt6+/+ | A/A cell lines treated with DMSO or SR1001.
(A) Representative flow cytometry histograms for GATA6 compared to Isotype control at the PFG
stage.
(B) Mean fluorescence Intensity (MFI) of GATA6 relative to MFI of Isotype at the PFG and PP
stages.
(C) Representative flow cytometry dot plot for SOX2 and NKX6.1 co-staining at the PP stage.
(D) Quantification of %PDX1+/NKX6.1+ double positive cells at the PP stage.
(E) Quantification of %PDX1+/SOX2+ double positive cells at the PP stage.
All data is represented as Mean+/- SEM. Ordinary one-way ANOVA with multiple comparisons
were used for statistics. *pvalue <0.05, **pvalue <0.01, ***pvalue <0.001, ****pvalue <0.0001.
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We also used siRNA to knockdown RORα specifically during pancreas specification.
Again, we hypothesized that the RORα siRNA should selectively reduce GATA6
expression only in the presence of the major allele G variant of rs12953985. RORα or
scrambled siRNAs were transfected 48 hours prior to the PFG stage and cells were
harvested at the PFG stage (Figure 3-11 A). We measured RORα protein expression
using immunofluorescence and RNA expression using qRT-PCR after transfection with
RORα or scrambled siRNAs (Figures 3-11 B and C). We found a significant reduction in
GATA6 protein expression at the PFG stage in the line with the G alleles while the line
with the A alleles were unaffected (Figures 3-11 D and E). Together, these data suggest
that modulation of RORα regulates pancreas development via GATA6.

3.2.7 Modifying the minor allele variant to a consensus RORα binding site rescues
GATA6 expression and pancreas differentiation

To confirm the effect of RORα on GATA6 expression, a RORα binding site was
introduced into the coding mutation corrected PA iPSC line expressing the minor allele
variant using CRISPR-CAS9 genome editing. Initial attempts to generate a single A to G
base pair change were unsuccessful due to indel formation (data not shown). To bypass
this technical hurdle, a consensus RORα motif was used in which two base changes to
the original sequence were introduced (Figure 3-12 A) and allowed the generation of
modified clones without indels. This line is designated as iPS+/+ | cons/cons (Table 3-1). The
iPS+/+

| A/A

and the iPS+/+

| cons/cons

lines were differentiated and GATA6 levels were

measured at the PFG and PP stages.
93

Figure 3-11:
3-11: RORα
disrupts
GATA6
expression
Figure
RORαsiRNA
siRNA
disrupts
GATA6
expression
A

hPS
OCT4
NANOG

3 days

DE
SOX17
FOXA2

3 days

2 days

RORα
siRNA

PFG
PDX1

β-like
Cells

Pancreas
Progenitor

Foregut
3 days

PP

2 days

7 days

14 days

β
C-peptide
NKX6.1

PDX1
NKX6.1

PFG

PFG
rora rna

C

Mel +/+ | G/G +RORα siRNA 13.2

wt
c41

Expression relative to TBP

Mel +/+ | G/G +scrambled siRNA

RORα

Hoesct

B

Mel +/+ | G/G
Mel +/+ | A/A

0.2
0.2

0.1
0.1

*

*

0

0.0

50um
sc
ra
mb
led

50um

RORα

0.3
0.3

*

Mel +/+ | G/G
Mel +/+ | A/A

10
10

5

5

0

sc

.2
13
si

ble
m
ra

ra

m

ble

d

GATA6

d

0

sc

Mel +/+ | G/G +scrambled siRNA
Mel +/+ | G/G +RORα siRNA 13.2
Mel +/+ | A/A +scrambled siRNA
Mel +/+ | A/A +RORα siRNA 13.2

PFG
15
15

.2

PFG

Day 8 GATA6 MFI sirna

13

E

si

D

GATA6 MFI relative to Isotype

da
y8

da
y8

ES +/+ | G/G
ES +/+ | A/A

si
13
.2

Definitive
Endoderm

Pluripotent
stem cells

Figure 3-11: RORα siRNA disrupts GATA6 expression during pancreas development
(A) Schematic of pancreas differentiation protocol from hPSCs. 10nM of RORα siRNA or scrambled
siRNA was added 2 days prior to the PFG stage.
(B) Immunofluorescence images for cells stained with RORα (red) and Hoechst (blue) at the PFG
stages in the Mel+/+ | G/G cell line with RORα siRNA and scrambled siRNA.
(C) qRT-PCR analysis of RORα at the PFG stage in Mel+/+ | G/G and Mel+/+ | A/A cell lines treated with
RORα siRNA or scrambled siRNA.
(D) Representative flow cytometry histograms for GATA6 compared to Isotype control at the PFG
stage for the Mel+/+ | G/G and Mel+/+ | A/A cell lines treated with RORα siRNA or scrambled siRNA.
(E) Mean fluorescence Intensity (MFI) of GATA6 relative to MFI of Isotype at the PFG and PP
stages for the Mel+/+ | G/G and Mel+/+ | A/A cell lines treated with RORα siRNA or scrambled siRNA.
All data is represented as Mean+/- SEM. Ordinary one-way ANOVA with multiple comparisons were
used for statistics. *pvalue <0.05, **pvalue <0.01, ***pvalue <0.001, ****pvalue <0.0001.

The introduced RORα consensus motif led to an ~30% increase in GATA6 protein levels
at the PFG and PP stages of the differentiation when compared to the iPS+/+
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| A/A

line

(Figures 3-12 B, C, D and Table 3-2). Increased NKX6.1+ cells were observed at the PP
stage (45 +/- 6 % vs. 27 +/- 4 %) (Figures 3-12 D, E and Table 3-3). These data confirm
that a functioning RORα binding site at rs12953985 in the patient iPSC line enhanced
the efficiency of pancreas differentiation to be more comparable to the wild type Mel1
line.
Figure
Introducing
a consensus
RORα
at rs12953985
in theiPS
patient
Figure 3-12:
3-12: Introducing
a consensus
RORα
motifmotif
at rs12953985
in the patient
cell iPS
cell
lines
improves
differentiation
efficiency
lines improves differentiation efficiency
A

B

rs12953985

gRNA PAM

PP

PFG

AAGAGACTTGACTGAAGTCCAGCTGAGG – Minor Allele
AAGAGACTTGACTGAGGTCAAGCTGAGG – Consensus RORα

iPS +/+ | A,A
iPS +/+ | cons/cons

RORα consensus
binding motif

Isotype

GATA6

C
GATA6 MFI relative to Isotype

D

ips+/+|A/A
ips+/+|cons/cons

GATA6 MFI fig1

PFG

1

PP

PFG

20
20

4

*

*

15
15

PP

3

2

iPS +/+ | A,A
iPS +/+ | cons/cons

10
10

Lanes 1 & 3 - iPS +/+ | A,A

GATA6

Lanes 2 & 4 - iPS +/+ | cons/cons

5

5

β Actin

0

0

iPS +/+ | GTAC/GTAC

PP

PFG
Day8

Day11

iPS +/+ | A/A

Day 11 SOX2+ / NKX6.1 -

Day 11 PDX1 / NKX6.1 +

iPS +/+ | GTAC/GTAC
iPS +/+ | A/A

4.3

SOX2

PP

54.8

39.8

49.3

100

G

100

PP

80
80

*

60
60

40
40

20
20

40
40

PP

30
30

iPS +/+ | A,A
iPS +/+ | cons/cons

ns
20
20

10
10

0

0

0

0

1

1

NKX6.1

38.5

F

1

6.5

% PDX1+ SOX2+

iPS
1.9

1

iPS
4.8

+/+ | cons/cons

% PDX1+ NKX6.1+

E

+/+ | A/A

Figure 3-12: Introducing a consensus RORα motif at rs12953985 in the patient iPS cell lines
improves differentiation efficiency
(A) Sequence of R5 around rs12953985. Changes to the minor allele variant are highlighted in red.
The green line represents the guide RNA used for targeting with the PAM sequence highlighted in
green.
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B-G) Data from iPS+/+|A/A and iPS+/+|cons/cons lines.
(B) Representative flow cytometry histograms for GATA6 compared to Isotype control at the PFG
and PP stages.
(C) Mean fluorescence Intensity (MFI) of GATA6 relative to MFI of Isotype at the PFG and PP
stages.
(D) Western blotting for GATA6 and loading control β-Actin at the PFG and PP stages. Lanes 1 and
3 represent iPS+/+|A/A lines at the PFG and PP stages respectively; Lanes 2 and 4 represent iPS+/+|
cons/cons lines at the PFG and PP stages respectively.
(E) Representative flow cytometry dot plot for SOX2 and NKX6.1 co-staining at the PP stage.
(F) Quantification of %PDX1+/NKX6.1+ double positive cells at the PP stage.
(G) Quantification of %PDX1+/SOX2+ double positive cells at the PP stage. All data represented
as Mean +/- SEM. Ordinary one-way ANOVA with multiple comparisons were used for statistics.
*pvalue <0.05, **pvalue <0.01, ***pvalue <0.001, ****pvalue <0.0001.
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3.3 Discussion
GWAS have identified many variants located in non-coding genomic regions that are
associated with gene expression in specific tissues and diseases (Boyle, Li and
Pritchard, 2017). The effect of these cis-acting non-coding variants on gene expression
have been proposed as a factor contributing to phenotypic variation of complex traits
and disease susceptibility (Castel et al., 2018). In fact, it has been suggested that there
could be a large number of disease-associated variants with decreasingly small effects
that could act in tandem to contribute to a stronger phenotype (Park et al., 2011).
Initiatives such as the GTEx project have identified many functional variants associated
with gene expression or eGenes (Consortium et al., 2017). However, these studies
depend on primary tissues from post-mortem donors, which are scarce. As a result,
information regarding the effects of variants during early human development is not
available. Genetically matched isogenic hPSCs lines developed using genome editing
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technologies such as CRISPR-CAS9 have proven to be a powerful tool to model the
effect of coding mutations during development. This study has expanded this model’s
applications to include the effects of coding and non-coding variants on gene expression
and disease penetrance during development.

Genome edited isogenic human patient-derived iPSCs and ESCs were generated to
interrogate the effect of a non-coding SNP on GATA6 expression during pancreas
development. This variant, rs12953985, in conjunction with a heterozygous GATA6
mutation reduced the efficiency of generating pancreatic progenitors in vitro. The
frequency of the minor allele of the SNP is enriched among patients with PA and was
found to be present in trans with the mutation in 7 PA patients. Since GATA6
heterozygous mutations are known to have variable clinical penetrance, the presence of
this non-coding variant provides a possible mechanistic explanation for the more severe
pancreatic agenesis phenotype, at least in some families. Our cohort mainly included
patients with PA (33 versus 10 patients with diabetes or congenital heart disease)
caused by de novo mutations (the mutation was inherited from a heterozygous parent in
4 cases) (Figure 3-4 and Table 3-4). This means that although our results are consistent
with the A allele of the rs12953985 SNP increasing the risk of pancreatic agenesis in
patients with pathogenic GATA6 mutations, further studies in larger cohorts are needed
to assess the effect size of the A allele of SNP rs12953985 on the pancreatic agenesis
risk and to identify further contributing factors. Other explanations for the varied
penetrance of GATA6 heterozygous mutations have been proposed. In the case of de
novo mutations, the most likely cause is mosaicism (De Franco, Shaw-Smith, Sarah E.
Flanagan, et al., 2013; Yu et al., 2014; Yau et al., 2017). In cases where the mutation is
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inherited, dosage levels of GATA4 and/or retinoic acid (RA) have been proposed as
possible causes for varied phenotypes in patients (Shi et al., 2017; Tiyaboonchai et al.,
2017)

We found that the minor allele variant of SNP rs12953985 leads to the disruption of a
RORα binding site. RORα is part of a family of nuclear receptors, also consisting of
RORβ and RORγ, that can function as transcription factors to regulate gene
expression(Chai et al., 2013). They bind as monomers to the consensus DNA motif
RGGTCA and can act as an “orphan” nuclear receptor to activate transcription even in
the absence of bound ligands (Chauvet et al., 2011). Ligand binding could lead to the
recruitment of either co-activator or co-repressor complexes, which suggests that RORα
could act as either a repressor or activator of gene expression (Solt and Burris, 2012).
By using a synthetic compound, SR1001, which binds to the ligand-binding domain of
RORα and increases the affinity for co-repressors, we were able to show that RORα can
regulate GATA6 expression only when then SNP major allele G variant is present during
pancreas specification (Figure 3-9 and 3-10)(Solt and Burris, 2012; Lin et al., 2017).
However, we do not rule out the possibility that other factors may differentially bind to
this site and regulate GATA6 as well.

Phenotypes observed in RORα mutant mice

revealed a role for RORα in modulating diet-induced obesity, insulin sensitivity and
glucose uptake (Lau et al., 2011; Billon, Sitaula and Thomas P. Burris, 2017). Studies
have also shown the expression of ROR receptors in pancreatic islet cells and RORα
regulates the expression of Ins2 in rat INS-1 cells (Mühlbauer et al., 2013; Kuang et al.,
2014). Moreover, RORα was identified as a diabetes susceptibility locus in Mexican
Americans and Han Chinese (Hayes et al., 2007; Zhang et al., 2016). Recently, a study
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of human embryos from late CS12 to early CS14 using laser capture of the developing
pancreas and liver have suggested a specific role for RORα in regulating pancreas
development (Jennings et al., 2017). Of the 655 transcription factors identified as key
pancreatic regulators in this study, 44% were predicted to be regulated by RORα using
motif discovery. These studies highlight the potential role for RORα as a regulator of the
pancreatic program in humans. While our study further strengthens these findings, a
more detailed analysis is needed to identify direct targets and pathways regulated by
RORα during pancreas development to determine if RORα influences other genes
regulating pancreas development and function as well as confirm its impacts on GATA6
expression.

Another interesting finding from our studies involves the cell fate switch where the
PDX1+ PFG cells develop into SOX2 expressing cells at the expense of NKX6.1
expression. It has been well established that the PDX1+/SOX2+ domain in the
developing mouse endoderm at E10.5 gives rise to the antral portion of the stomach
(Willet and Mills, 2016; McCracken et al., 2017). Experiments in mouse models of PA
caused by knocking out GATA6 and GATA4 have shown that at E10.5 of mouse
development, pancreatic lineage cells in the dorsal pancreatic endoderm switch to a
stomach identity by expressing SOX2. Similarly, in the ventral pancreatic endoderm, the
pancreatic lineages appear to adopt intestinal cell fates by expressing CDX2. This study
concludes that the erroneous upregulation of the hedgehog pathway in the
GATA6/GATA4 double knock out embryos results in re-specification of the dorsal and
ventral pancreatic lineages to the adjacent stomach and intestinal fates, respectively
(Xuan and Sussel, 2016). RNAseq data from another group looking at GATA6 mutant
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cells during in vitro pancreas differentiation from ESCs also show an upregulation of
SOX2 caused by heterozygous GATA6 mutations (Shi et al., 2017). Additionally, in a
patient suffering from dorsal PA, contrast CT imaging showed the presence of stomach
and bowel loops in the distal pancreatic bed (Sandip et al., 2016). Taken together, these
results suggest that GATA6 haploinsufficiency leads to a fate switch in the PDX1+
population from NKX6.1+ pancreas progenitors to SOX2+ antral stomach progenitors.

In summary, we have highlighted the use of patient derived stem cell lines to identify
genome variants that may be contributing to changes in gene expression during certain
stages of human development. Using genetically identical hPSC lines and CRISPRCAS9 gene editing, we identified a non-coding SNP that influences GATA6 regulation
and could contribute to a stronger PA phenotype. Our results highlight a possible role for
RORα during pancreas specification in humans. Further studies will be important to
further define the role of the ROR family in pancreas development and identify other
non-coding variants in patients that could contribute to disease penetrance.

Table 3-1. hPSC lines generated
rs12953985

Line
name

Genetic
background

GATA6 allele 1

GATA6 allele 2

Mel+/+|G/G

Mel1

Wild type

Wild type

G|G

Mel+/mut|G/G

Mel1

Wild type

c. 627630dupCAGT

G|G

Mel+/+|A/A

Mel1

Wild type

Wild type

A|A
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Genotype

Mel+/mut|A/A

Mel1

Wild type

c. 627630dupCAGT

A|A

iPS+/+|A/A

CHOP.Panagen
esis1

Wild type

Wild type

A|A

iPS+/mut|A/A

CHOP.Panagen
esis1

Wild type

c. 606609dupGTAC

A|A

iPS+/+|cons/c
oms

CHOP.Panagen
esis1

Wild type

Wild type

RORα
consensus|
RORα
consensus

CHOPWT
6+/+|G/G

CHOPWT6 iPS

Wild type

Wild type

G|G

CHOPWT
6+/mut|G/G

CHOPWT6 iPS

Wild type

c. 627630dupCAGT

G|G

CHOPWT
6+/+|A/A

CHOPWT6 iPS

Wild type

Wild type

A|A

CHOPWT
6+/mut|A/A

CHOPWT6 iPS

Wild type

c. 627630dupCAGT

A|A
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Table 3-2. GATA6 MFI measurements relative to Isotype in Figures 3-1 G, 3-6 B, 3-9
G and 3-12 C

Line

iPS+/+
Figure 3-1
G

iPS+/mut
Figure 3-1
G

Mel+/+
Figure 3-1
G

Mel+/mut
Figure 3-1
G

Mel +/+ | G/G
Figure 3-6
B

N

Stage of

GATA6 MFI

Differentiation

(Mean +/- SEM)

(Number of biological
replicates)

DE

11.053 +/- 1.283

5

PFG

8.664 +/- 0.685

8

PP

9.330 +/- 0.634

7

DE

10.982 +/- 1.183

4

PFG

6.251 +/- 0.420

10

PP

7.267 +/- 0.354

7

DE

11.107 +/- 0.773

6

PFG

12.335 +/- 1.127

6

PP

15.385 +/- 0.616

6

DE

8.705 +/- 0.922

6

PFG

8.342 +/- 0.849

6

PP

9.874 +/- 0.786

7

DE

11.107 +/- 0.773

6

PFG

12.907 +/- 1.031

10

PP

14.085 +/- 0.828

10
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Mel +/+ | A/A

DE

9.183 +/- 0.583

5

Figure 3-6
B

PFG

10.046 +/- 0.731

10

PP

11.439 +/- 0.610

10

DE

8.705 +/- 0.922

6

PFG

8.823 +/- 0.779

9

PP

9.774 +/- 0.431

6

DE

9.471 +/- 0.557

5

Figure 3-6
B

PFG

7.423 +/- 0.514

10

PP

7.689 +/- 0.452

9

Mel +/+ | G/G

PFG

12.032 +/- 1.984

4

Figure 3-9
G

PP

10.540 +/- 1.557

4

Mel +/+ | G/G

PFG

8.090 +/- 1.340

4

Figure 3-9
G

PP

8.604 +/- 1.798

4

Mel +/+ | A/A

PFG

6.396+/- 0.754

4

Figure 3-9
G

PP

6.116 +/- 1.858

4

Mel +/+ | A/A

PFG

6.166+/- 1.279

4

PP

6.496 +/- 2.108

4

Mel +/mut | G/G
Figure 3-6
B

Mel +/mut | A/A

+DMSO

+SR1001

+DMSO

+SR1001
Figure 3-9
G
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iPS +/+ | A/A

PFG

8.664 +/- 0.685

8

Figure 3-12
C

PP

9.330 +/- 0.634

7

iPS +/+ |

PFG

13.286 +/- 1.281

4

Figure 3-12
C

PP

12.769 +/- 1.349

5

cons/cons

Table 3-3. Percentage of PDX1+/NKX6.1+ and PDX1+/SOX2+ cells at the PP stage
in Figures 3-1 D, 3-1 E, 3-6 E, 3-6 F, 3-9 I, 3-12 F
N
Line

iPS+/+

% Of cells

Type of cells

(Mean +/- SEM)

(Number of
biological
replicates)

PDX1+ / NKX6.1+

31.08 +/- 3.277

4

PDX1+ / SOX2+

7.918 +/- 0.8555

5

PDX1+ / NKX6.1+

10.09 +/- 6.058

4

PDX1+ / SOX2+

21.38 +/- 3.869

6

PDX1+ / NKX6.1+

60.33 +/- 4.298

7

PDX1+ / SOX2+

6.800 +/- 1.931

5

PDX1+ / NKX6.1+

28.15 +/- 2.452

4

PDX1+ / SOX2+

18.83 +/- 0.9503

8

Mel +/+ | G/G

PDX1+ / NKX6.1+

60.81 +/- 3.076

14

Figures 3-6 E
and F

PDX1+ / SOX2+

6.800 +/- 1.931

5

Figures 3-1 D
and E
iPS+/mut
Figures 3-1 D
and E
Mel+/+
Figures 3-1 D
and E
Mel+/mut
Figures 3-1 D
and E
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Mel +/+ | A/A

PDX1+ / NKX6.1+

37.77 +/- 3.107

15

Figures 3-6 E
and F

PDX1+ / SOX2+

11.50 +/- 1.439

8

Mel +/mut | G/G

PDX1+ / NKX6.1+

35.03 +/- 5.371

8

Figures 3-6 E
and F

PDX1+ / SOX2+

18.83 +/- 0.9503

8

Mel +/mut | A/A

PDX1+ / NKX6.1+

22.47 +/- 4.674

8

Figures 3-6 E
and F

PDX1+ / SOX2+

26.68 +/- 1.972

5

Mel +/+ | G/G
+DMSO

PDX1+ / NKX6.1+

52.9 +/- 10.18

4

PDX1+ / NKX6.1+

35.075 +/- 10.341

4

PDX1+ / NKX6.1+

39.05 +/- 8.704

4

PDX1+ / NKX6.1+

38.55 +/- 9.263

4

PDX1+ / NKX6.1+

27.38 +/- 4.111

5

PDX1+ / NKX6.1+

45.27 +/- 6.116

4

Figure 3-9 I
Mel +/+ | G/G
+SR1001
Figure 3-9 I
Mel +/+ | A/A
+DMSO
Figure 3-9 I
Mel +/+ | A/A
+SR1001
Figure 3-9 I
iPS +/+ | A/A
Figure 3-12 E
iPS +/+ | cons/cons
Figure 3-12 E

Each biological replicate is a new differentiation from pluripotent stem cells. From
every biological replicate, cells were harvested at different stages of the differentiation.
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Table 3-4. PA patient information

De novo

Pancreatic
phenotype

rs12953985
genotype

SNP A
allele and
mutation
in trans

Country

Chicag
o #1

c.1366C>
T,
p.(Arg45
6Cys)

Not
known
(parents
not
available)

Pancreatic
agenesis

A/G

Not known

USA

Chicag
o #2

c.1087_1
097del,
p.(Gln36
3fs)

Not
known
(parents
not
available)

Pancreatic
agenesis

A/G

Not known

USA

Chicag
o #3

c.1366C>
T,
p.(Arg45
6Cys)

Not
known
(parents
not
available)

Pancreatic
agenesis

A/A

Yes

USA

Chicag
o #4

c.1291_1
300del,
p.(Gln43
1fs)

yes

Pancreatic
agenesis

A/A

Yes

USA

Chicag
o #5

c.785G>
A,
p.(Arg26
2His)

Not
known
(parents
not
available)

Diabetes
diagnosed
at age 23

A/G

Not known

USA

Chicag
o
N6320

c.1366C>
T,
p.(Arg45
6Cys)

Not
known
(parents
not
available)

Diabetes
diagnosed
at age 16

A/G

Not known

USA

CHOP.
Panage
nesis1

c.606_60
9dup,
p.(His204
fs)

Not
known
(parents
not
available)

Pancreatic
agenesis

A/A

Yes

USA

Patient
ID

GATA6
Mutation
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Exeter_
01

c.1406G
>A,
p.(Gly469
Glu)

No

Pancreatic
agenesis

A/A

Yes

Netherla
nds

Exeter_
01M

NA

NA

NA

A/A

NA

Netherla
nds

Exeter_
01F

c.1406G
>A,
p.(Gly469
Glu)

Not
known
(parents
not
available)

Diabetes

G/A

No

Netherla
nds

Exeter_
02

c.1417A>
C,
p.(Lys47
3Gln)

Yes

Pancreatic
agenesis

G/A

Not known

Netherla
nds

Exeter_
02M

NA

NA

NA

G/G

NA

Netherla
nds

Exeter_
02F

NA

NA

NA

G/A

NA

Netherla
nds

Exeter_
03

c.13031G>T,
p.?

No

Pancreatic
agenesis

G/A

Not known

United
Kingdom

Exeter_
03M

c.13031G>T,
p.?
Mosaic

Yes

No

G/A

Not known

United
Kingdom

Exeter_
04

c.635_66
0del,
p.(Pro21
2fs)

No

Pancreatic
agenesis

G/A

Yes

Canada

Exeter_
04M

c.635_66
0del,
p.(Pro21
2fs)
Mosaic

Yes

No

G/A

Not known

Canada
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Exeter_
04F

NA

NA

NA

G/A

NA

Canada

Exeter_
04S1

NA

NA

NA

G/A

NA

Canada

Exeter_
04S2

c.635_66
0del,
p.(Pro21
2fs)

No

No (heart
disease)

G/G

NA

Canada

Exeter_
04S3

c.635_66
0del,
p.(Pro21
2fs)

No

Small
pancreas
with normal
islets

G/G

NA

Canada

Exeter_
05

c.1013C>
A,
p.(Ser33
8*)

Yes

Pancreatic
agenesis

G/G

NA

United
Kingdom

Exeter_
05M

NA

NA

NA

G/G

NA

United
Kingdom

Exeter_
05F

NA

NA

NA

G/G

NA

United
Kingdom

Exeter_
06

c.(?_1)_(1788
+1_?)del,
p.?

Yes

Pancreatic
agenesis

A/A

Yes

Germany

Exeter_
06M

NA

NA

NA

G/A

NA

Germany

Exeter_
06F

NA

NA

NA

G/A

NA

Germany

Exeter_
07

c.877_88
0delinsT
AC,
p.(Val293
fs)

Not
known
(parents
not
available)

Pancreatic
agenesis

G/A

Not known

USA
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Exeter_
08

c.1330T>
C,
p.(Cys44
4Arg)

No

Pancreatic
agenesis

G/G

NA

Australia

Exeter_
08M

NA

NA

NA

G/G

NA

Australia

Exeter_
08F

c.1330T>
C,
p.(Cys44
4Arg)

Not
known
(parents
not
available)

No (heart
disease)

G/G

NA

Australia

Exeter_
09

c.1367G
>A,
p.(Arg45
6His)

Yes

Transient
neonatal
diabetes

G/G

NA

USA

Exeter_
09M

NA

NA

NA

G/A

NA

USA

Exeter_
09F

NA

NA

NA

G/G

NA

USA

Exeter_
10

c.214G>
T,
p.(Gly72*
)

Not
known
(not in
mother,
father not
available)

Diabetic
(diagnosed
at 13
years)

G/G

NA

United
Kingdom

Exeter_
10M

NA

NA

NA

G/G

NA

United
Kingdom

Exeter_
11

c.1367G
>A,
p.(Arg45
6His)

Yes

Pancreatic
agenesis

G/G

NA

United
Kingdom

Exeter_
11M

NA

NA

NA

G/G

NA

United
Kingdom
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Exeter_
11F

NA

Exeter_
12

NA

NA

G/G

NA

United
Kingdom

c.1396A>
G,
p.(Asn46
6Asp)

Yes

Diabetic
(diagnosed
at 12
years)

A/A

Yes

United
Kingdom

Exeter_
12M

NA

NA

NA

G/A

NA

United
Kingdom

Exeter_
12F

NA

NA

NA

A/A

NA

United
Kingdom

Exeter_
13

c.1108_1
121dup,
p.(Gly375
Sfs)

Yes

Pancreatic
agenesis

A/A

Yes

Sweden

Exeter_
13M

NA

NA

NA

A/A

NA

Sweden

Exeter_
13F

NA

NA

NA

A/A

NA

Sweden

Exeter_
14

c.1366C>
T,
p.(Arg45
6Cys)

Yes

Pancreatic
agenesis

A/A

Yes

United
Kingdom

Exeter_
14M

NA

NA

NA

G/A

NA

United
Kingdom

Exeter_
14F

NA

NA

NA

G/A

NA

United
Kingdom

Exeter_
15

c.142941_1441
del, p.?

Yes

Pancreatic
agenesis

G/G

NA

Germany

Exeter_
15M

NA

NA

NA

G/A

NA

Germany
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Exeter_
15F

NA

NA

NA

G/A

NA

Germany

Exeter_
16

c.14298T>G,
p.?

Yes

Pancreatic
agenesis

G/G

NA

Germany

Exeter_
16M

NA

NA

NA

G/G

NA

Germany

Exeter_
16F

NA

NA

NA

G/G

NA

Germany

Exeter_
17

c.1435A>
G,
p.(Arg47
9Gly)

Yes

Transient
neonatal
diabetes

G/G

NA

Netherla
nds

Exeter_
17M

NA

NA

NA

G/A

NA

Netherla
nds

Exeter_
17F

NA

NA

NA

G/G

NA

Netherla
nds

Exeter_
18

c.1498_1
501del,
p.(Lys50
0fs)

Yes

Pancreatic
agenesis

G/A

Not known

Netherla
nds

Exeter_
18M

NA

NA

NA

G/G

NA

Netherla
nds

Exeter_
18F

NA

NA

NA

A/A

NA

Netherla
nds

Exeter_
19

c.1516+1
G>C, p.?

Yes

Pancreatic
agenesis

G/A

Not known

USA

Exeter_
19M

NA

NA

NA

G/A

NA

USA
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Exeter_
19F

NA

NA

NA

n/a

NA

USA

Exeter_
20

c.1448_1
455del,
p.(Met48
3fs)

Yes

Pancreatic
agenesis

G/A

Not known

New
Zealand

Exeter_
20M

NA

NA

NA

G/G

NA

New
Zealand

Exeter_
20F

NA

NA

NA

G/A

NA

New
Zealand

Exeter_
21

c.-(265?_1135+
?del), p.?

Not
known
(not in
mother,
father not
available)

Pancreatic
agenesis

G/A

Not known

United
Kingdom

Exeter_
21M

NA

NA

NA

G/A

NA

United
Kingdom

Exeter_
22

c.1399G
>A,
p.(Ala467
Thr)

Not
known
(parents
not
available)

Pancreatic
agenesis

G/G

Exeter_
23

c.1036_1
042del,
p.(Thr346
fs)

No

Pancreatic
agenesis

A/A

Yes

Germany

Exeter_
23M

NA

NA

NA

G/A

NA

Germany

Exeter_
23F

c.1036_1
042del,
p.(Thr346
fs)

Not
known
(not in
mother,
father not
available)

Diabetes
(diagnosed
at 46)

G/A

No

Germany
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USA

Exeter_
24

c.701del,
p.(Pro23
4fs)

Yes

Pancreatic
agenesis

G/A

Not known

Kosovo

Exeter_
24M

NA

NA

NA

G/G

NA

Kosovo

Exeter_
24F

NA

NA

NA

G/A

NA

Kosovo

Exeter_
25

c.130310C>G,
p.?

Yes

Pancreatic
agenesis

G/G

NA

United
Kingdom

Exeter_
25M

NA

NA

NA

G/G

NA

United
Kingdom

Exeter_
25F

NA

NA

NA

G/G

NA

United
Kingdom

Exeter_
26

c.1396A>
G,
p.(Asn46
6Asp)

Not
known
(not in
mother,
father not
available)

Pancreatic
agenesis

G/A

Not known

Australia

Exeter_
26M

NA

NA

NA

G/A

NA

Australia

Exeter_
27

c.1366C>
T,
p.(Arg45
6Cys)

Yes

Pancreatic
agenesis

G/G

NA

Canada

Exeter_
27M

NA

NA

NA

n/a

NA

Canada

Exeter_
27F

NA

NA

NA

n/a

NA

Canada

Exeter_
28

c.969C>
A,
p.(Tyr323

No

Pancreatic
agenesis

G/A

Yes

Czech
Republic
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*)

Exeter_
28M

NA

NA

NA

A/A

NA

Czech
Republic

Exeter_
28F

c.969C>
A,
p.(Tyr323
*)

Yes

Diabetes
(diagnosed
at 30)

G/G

NA

Czech
Republic

Exeter_
29

c.1296del
,
p.(Lys43
2fs)

Yes

Pancreatic
agenesis

G/A

Not known

United
Kingdom

Exeter_
29M

NA

NA

NA

G/G

NA

United
Kingdom

Exeter_
29F

NA

NA

NA

A/A

NA

United
Kingdom

Exeter_
30

c.744del,
p.(Pro24
9fs)

Yes

Pancreatic
agenesis

G/A

Not known

Canada

Exeter_
30M

NA

NA

NA

G/A

NA

Canada

Exeter_
30F

NA

NA

NA

G/G

NA

Canada

Exeter_
31

c.1369A>
G,
p.(Arg45
7Gly)

Yes

Pancreatic
agenesis

G/A

Not known

USA

Exeter_
31M

NA

NA

NA

G/G

NA

USA

Exeter_
31F

NA

NA

NA

G/A

NA

USA
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CHAPTER 4: SUMMARY AND FUTURE DIRECTIONS

4.1 Other non-coding disease modifiers of PA
The major finding in this study is the disease modifying SNP rs12953985. The minor
allele variant of this SNP in conjunction with a heterozygous mutation in the GATA6
coding region leads to a stronger PA disease phenotype. In this study we found that the
minor allele, A, was more frequent among patients with PA compared to the non-PA
group. The A allele was present in 25/33 individuals with GATA6 PA tested in the two
cohorts for a cumulative allele frequency of 48.5%. This is higher than the allele
frequency among patients with the GATA6 mutation without PA (27.8%) and the
frequency among Europeans in the GnomAD database (33.5%).

We also found cases where patients suffer from PA while having the major allele variant,
G, of rs12953985. We hypothesize that in these cases there may be other direct genetic
modifiers of GATA6 expression or a modifier of genes upstream of GATA6. If this is the
case, a more detailed study of PA patient genomes using whole genome sequencing or
deep sequencing of regions of interest around pancreas specific genes would be needed
to identify other modifiers. In this study, we have identified 6 non-coding regions of
interest based on histone marks and transcription factor binding. While we did not find
any variants in this region in our CHOP.Panagenesis iPS cell line, these regions could
hold variants of interest in other patient samples. Sequencing these regions will yield a
deeper understanding on the different variants that could contribute to the more severe
PA phenotype.
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Previous studies have also shown that retinoic acid (RA) signaling and GATA4
expression levels could play a role in the severity of phenotype (Shi et al., 2017;
Tiyaboonchai et al., 2017). In the case of morphogen signaling pathways like RA, lower
doses of RA in hPSC differentiation models led to lower GATA6 levels, which in turn led
to fewer pancreas progenitors. It would be interesting to screen for variants in RA
pathway genes in our patient cohort. Additionally, this study and others have shown that
GATA factors regulate each other; specifically GATA6 regulates GATA4 during human
pancreas development. In some cases, an additional variant in the GATA4 locus could
be leading to the more severe PA phenotype. While we have identified one disease
modifying variant of PA, we believe further research will yield more such modifiers and
provide a deeper understanding of the pathogenesis of PA.

4.2 Identifying additional downstream targets of GATA6
While this study has highlighted an upstream regulator of GATA6 expression, some
questions regarding the downstream targets of GATA6 are still unexplored. We have
shown that mutations in GATA6 lead to a decrease in GATA6 expression levels, which
in turn cause a reduction in pancreas progenitor gene signature, specifically in genes
such as GATA4, PDX1, NKX6-1 and others. We have also shown that this causes an
increase in stomach progenitor gene signature, specifically in SOX2 and IRX2.

What remains to be understood is how GATA6 regulates the expression of these genes.
This could be either by direct regulation of the transcription of these genes or an indirect
regulation or a combination of the two. These questions can be best answered by
performing ChIP-seq for GATA6 at the foregut stage of the differentiation. This would
117

help elucidate the potential direct targets of GATA6. Once we identify the regions that
show GATA6 binding, we can then measure RNA and protein levels of nearby genes to
conclusively answer the question of direct vs indirect regulation. If this approach is
inconclusive, an unbiased approach of an RNA-seq could be very useful to elucidate all
the genes dysregulated by GATA6 haploinsufficiency. We could then use gene ontology
to identify potential gene networks and signaling pathways that may be affected by
GATA6 mutations. Using this information, we can tweak these signaling pathways using
small molecules during the hPSC pancreas differentiation and attempt to rescue the
pancreas progenitor phenotype.

Additionally, if we identify GATA6 binding in the regulatory regions of SOX2 during
pancreas development, this could suggest a direct regulation of SOX2 by GATA6,
providing a mechanism for the fate switch from pancreas to stomach progenitors. To test
whether GATA6 is repressing SOX2 expression by binding at regulatory regions, we can
modify these GATA6 binding motifs and observe the effect on SOX2 expression levels.
Loss of GATA6 binding to these mutated regions should lead to an increase in SOX2
gene expression specifically at the pancreas progenitor stage of the differentiation.

These studies could also provide some insight into the differences in gene regulation
between humans and murine models. As pancreas differentiation protocols are
becoming more sophisticated and we are getting closer to generating a functional adult
β-cells from PSCs, any deeper insight into human specific pancreas gene regulation will
be invaluable. This study has highlighted a key difference in human and mice pancreas
development at a human specific regulatory region. We may also be able to decipher
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human specific gene regulatory networks governed by GATA6 that leads to a more
severe phenotype in humans as compared to mice.

4.3 Elucidating the role of GATA6 in gut tube patterning
One of the most interesting findings in this study is the switch in the cell fate of PP cells
with lower GATA6 levels. We have shown that with decreasing GATA6 levels the PDX1+
PFG cells develop into SOX2 expressing cells at the expense of NKX6.1 expression.
Our data supports the idea that GATA6 is involved in anterior/posterior patterning of the
gut tube, which is consistent with our previous work looking at GATA6 in anterior
endoderm patterning (Liao et al., 2018). In both cases decreased expression of GATA6
leads to marker expression indicative of anteriorization (Figure 4-1).

A further mechanistic analysis of how GATA6 patterns the gut tube is the logical next
step. In mice it has been shown that GATA4 and GATA6 are essential for maintaining
repression of hedgehog signaling in the gut tube (Xuan and Sussel, 2016). GATA4 and
GATA6 are able to repress transcription through the sonic hedgehog (Shh) endodermspecific enhancer MACS1 and that GATA-binding sites within this enhancer are
necessary for this repressive activity. This leads to a switch in cell fate of pancreas
progenitor cells in the developing mice gut tube. To confirm this in the hPSC model
system, we would need to increase the external Shh inhibition with lowering doses of
GATA6 in order to rescue the phenotype. Conversely, removing the exogenous Shh
inhibition under wild type conditions with normal levels of GATA6 should lead to no
change in pancreas specification.
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Figure 4-1: Elucidating the role of GATA6 in gut tube patterning
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Figure 4-1: Elucidating the role of GATA6 in gut tube patterning
The foregut, midgut and hindgut segments of the gut tube are indicated along with the budding
organs from each of these patterned segments. Morphogen gradients of FGF, Wnt, BMP, RA and
Hedgehog (Hh) play a key role in specifying where these organ buds develop. These are marked
by transcription factors such as SOX2, PDX1 and CDX2. GATA6 mutations, which lead to lower
levels of GATA6 protein, cause an anteriorization phenotype, which suggests that GATA6 acts as a
posteriorizing factor during gut tube patterning. The exact mechanism of this is still unknown and
future work will determine what morphogen gradients are regulated by GATA6.

Another possible explanation for the patterning defect caused by GATA6 could by
dysregulation of the Wnt signaling pathway. RNAseq data from the PP stage in GATA6
deficient cells show a number of Wnt pathway genes that are dysregulated (Shi et al.,
2017). These include upregulation of different Wnts and their receptors. Additionally in
the mouse embryos, loss of Wnt/β-catenin signaling in the developing stomach leads to
posteriorization of the fundus to the antrum (McCracken et al., 2017). β-catenin
activation in hPSC-derived foregut progenitors promoted the anteriorization of
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developing stomach and the development of human fundic-type gastric organoids
(hFGOs). To test whether lower GATA6 levels lead to an upregulation of Wnt/β-catenin
signaling pathway, genes that are downstream of this pathway need to be measured at
the PFG and PP stages of the pancreas differentiation. Additionally, the anteriorization
phenotype that we observe should be rescued by using a Wnt inhibitor at these specific
stages.

These studies would provide important implications for the pathways regulated by the
GATA factors during human gut tube development and could lead to novel strategies to
detect and/or prevent PA before birth.

4.4 Deciphering the role of GATA6 in stomach development
We have identified an increase in antral stomach markers SOX2 and IRX2 in the
pancreas progenitor cells with lower GATA6 levels. This finding brings into question the
role of GATA6 during human stomach development. Experiments in mouse models of
PA caused by knocking out GATA6 and GATA4 have shown that at E10.5 of mouse
development, pancreatic lineage cells in the dorsal pancreatic endoderm switch to a
stomach identity by expressing SOX2 (Xuan et al., 2012). RNAseq data from another
group looking at GATA6 mutant cells during in vitro pancreas differentiation from ESCs
also show an upregulation of SOX2 caused by heterozygous GATA6 mutations (Shi et
al., 2017). Additionally, in a patient suffering from dorsal PA, contrast CT imaging
showed the presence of stomach and bowel loops in the distal pancreatic bed (Sandip et
al., 2016).
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The role of GATA factors in human stomach development is not very well understood.
Stomach differentiation protocols from hPSCs to study stomach development have been
a fairly recent advancement in the field. Our genetically matched cell lines with
decreasing GATA6 levels may prove to be a perfect model system to understand human
stomach development. The hypothesis is that with lower levels of GATA6 we see more
of a bias towards fundic cell fate as opposed to an antral cell fate. There are a few
experiments of interest. Firstly, it would be interesting to see if the regulatory regions that
we identified in our study are also active during stomach development. Secondly, the
stage specific regulation of stomach development by GATA6 would give us insights into
time points at which the GATA factors are necessary.

GATA6 and GATA4 have been shown to play a role in gastric cancers and more recently
there is burgeoning evidence indicating their importance in stomach development. The
genetic models that we have developed in this study can be very useful to develop a
deeper understanding of the role of GATA factors during human stomach development.

4.5 Understanding the role of RORα during human pancreas development
Our study highlights the potential role for RORα as a regulator of the pancreatic program
in humans. We have shown that RORα regulates GATA6 expression specifically during
pancreas development by binding to a downstream regulatory region. While this is a
good initial step into dissecting the role of RORα, a deeper dive into the function of
RORα during human pancreas development is important.
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To this date, the most compelling evidence for the specific role of RORα in human
pancreas development is from a recent study of human embryos from late CS12 to early
CS14 using laser capture of the developing pancreas and liver (Jennings et al., 2017).
Of the 655 transcription factors identified as key pancreatic regulators in this study, 44%
were predicted to be regulated by RORα using motif discovery. This study uses a purely
bioinformatics approach to decipher the potential role of RORα in human pancreas
development. To achieve a more detailed understanding, using genome-edited hPSCs
with genetically matched RORα mutant and wild type lines will be beneficial. One
particular downside of knocking out RORα is that other members of the ROR family,
which bind to a highly conserved DNA binding motif, could compensate its role. If this
were to be the case, knocking our RORα will have little to no phenotype on pancreas
development. To circumvent this, generating a specific dominant negative form of RORα
may be beneficial. This would have a similar effect to the inverse agonist SR1001 that
we used in our study. A genetically modified cell line will also have fewer off-target
effects compared to a small molecule like SR1001. Additionally, to identify specific
targets, ChIP-seq for RORα at the FG and PP stages of the differentiation should be
performed. These binding data would also need to be correlated with gene expression
studies to identify gene networks that are controlled by RORα.

While our study further strengthens the role of RORα during human pancreas
development, a more detailed analysis is needed to identify direct targets and pathways
regulated by RORα and to determine if RORα influences other genes regulating
pancreas development and function as well as confirm its impacts on GATA6
expression.
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4.6 Involvement of other nuclear receptors in regulating GATA6
We have identified an orphan nuclear receptor, RORα, which regulates GATA6 by
binding to a downstream regulatory region. RORα has previously been implicated in
insulin sensitivity, diet-induced obesity and glucose uptake in mice (Lau et al., 2011;
Billon, Sitaula and Thomas P. Burris, 2017). Interestingly RORα has also been identified
as a diabetes susceptibility locus in Mexican Americans and Han Chinese (Hayes et al.,
2007; Zhang et al., 2016). While there have been links between RORα and pancreatic
diseases, the phenotypes are not as severe as those seen with GATA6 mutations. One
reason for this may be the redundancy between nuclear receptors and the fact that other
nuclear receptors bind to similar DNA binding motifs and may compensate for the loss of
RORα.

Recent studies have shown that other nuclear receptors can also bind as monomers to
the RGGTCA motif (Quack and Carlberg, 2001; Penvose et al., 2019). Of particular
interest is another orphan nuclear receptor, NR5A2, which has been shown to play a
role in pancreas development and the maintenance of pancreatic exocrine identity (Hale
et al., 2014). NR5A2 is a member of the nuclear hormone receptor family and they bind
as monomers to extended half-site DNA response elements. NR5A2 has been shown to
be crucial during fetal organogenesis for the formation of the pancreas. It controls the
expansion of the nascent pancreatic epithelium, the proper formation of the pancreas
progenitor population that gives rise to pre-acinar cells and bipotent cells with ductal and
islet endocrine potential, and the proper formation and differentiation of pre-acinar cells.
NR5A2 has also been shown to play a critical role in regulating pancreatic transcription
factors such as GATA4 and FOXA2 (Hale et al., 2014). NR5A2 may be playing a
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compensatory role in regulating GATA6 in the cases where mutations lead to loss of
RORα function.

To test this hypothesis, we could generate a RORα knockout in the context of wild type
and GATA6 heterozygous mutations. If these lines do not have the same phenotype as
the minor allele of SNP rs12953985, we could look for compensation by binding of
NR5A2 to this site.
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